

## **Supplementary materials**

### **The immune response to childhood vaccines is seasonal**

Barrero Guevara, LA1, Féghali G1, Kramer SC1, Domenech de Cellès M1

1. Max Planck Institute for Infection Biology, Infectious Disease Epidemiology Group, Campus Charité Mitte, Berlin, Germany

#### **Supplementary methods**

##### **Data selection**

We obtained data from 265 randomized clinical trials (RCTs) of vaccines for childhood infections via the ClinicalStudyDataRequest.com (CSDR) platform (Supplementary Table 1). We excluded 144 initially because they did not meet the study population criteria, had missing data, or were duplicates (14, 64, and 66 studies, respectively; Supplementary Figure 1). We then classified each RCT according to at least one of 14 pathogen groups, provided the vaccines against the specific pathogen were applied to children for the first time, and the immunogenicity was subsequently measured. In addition, four studies were excluded because they lacked pathogen-specific baseline antibody measurements, which we required to assess or confirm prior exposure to the pathogen. The remaining 117 studies, including 85,165 participants, were evaluated for inclusion at the participant level. Of these, only 110 studies were retained, as they contained complete records for age, sex, vaccine applied, vaccination date, vaccine concentration, immunogenicity measurement, immunogenicity date, immunogenicity result, and immunogenicity method. Furthermore, baseline antibody measurements had to be obtained within 30 days of the primary vaccination, yielding baseline seronegative immunogenicity results. Participants also needed to be at least 1 month old at the time of first vaccination, with age restrictions set at under 26 months for measles, mumps, rubella, and HAV vaccinations, or under 6 months for all other pathogen vaccinations. Additionally, the time between vaccination and serology testing had to be less than 6 months. Due to anonymization, most studies reported only participants' country of residence. Because countries can cover large areas, to better define participants' locations, we extracted center locations from the GSK database (<https://www.gsk.com/en-gb/>) and assigned each to a latitudinal group. Because center locations could not be traced back to each participant due to anonymization procedures, participants were included only if more than 80% of their locations within their country fell into the same latitudinal group. When the study did not provide any center locations, we defined them based on the capital cities of the first-level administrative divisions. Finally, our data comprised 96 studies, involving 48,318 participants.

#### **Supplementary results**

##### **Characteristics of vaccinated individuals, vaccine schedules, and the vaccines influence immunogenicity**

Intrinsic characteristics of the vaccinated individuals, vaccine schedules, and vaccines strongly shaped the immune response (Figure 4). Across vaccines, and consistent with

previous studies<sup>1,2</sup>, males showed weaker immune responses than females. This sex difference was consistently detected for all vaccines administered at 1 year of age—measles, mumps, rubella, varicella, and HAV—and for most of the earlier-infancy vaccines, including rotavirus, *H. influenzae B*, and tetanus (Range of estimates [95% credible interval (CI)] = -11.24% [-15.18%, -7.29%], -4.02% [-7.56%, -0.50%]). In addition, as found in other studies<sup>3,4</sup>, age at vaccination also had a clear positive effect on immunogenicity, with older infants displaying stronger responses. Interestingly, this effect appeared milder for vaccines given at 1 year of age (Range of estimates [95% CI] = 0.34% [0.19%, 0.48%], 2.68% [0.75%, 4.69%]) compared with those administered in early infancy (Range of estimates [95% CI] = 2.75% [1.45%, 4.05%], 6.90% [5.04%, 8.76%]), a pattern consistent with rapid developmental maturation of the infant immune system.

Other characteristics of the vaccine schedules also affected the immune response after vaccination (Figure 4). As described in other studies<sup>5-7</sup>, we found that longer intervals between successive doses enhanced the antibody response for diphtheria, polio, and HBV, both between the first-to-second (Estimates [95% CI] = 0.78% [0.44%, 1.12%], 1.65% [1.08%, 2.22%], and 2.15% [1.21%, 3.10%], respectively) and with a milder effect the second-to-third doses (Estimates [95% CI] = 0.33% [0.01%, 0.65%], 1.00% [0.46%, 1.54%], and 1.45% [0.89%, 2.00%], respectively). In contrast, for *N. meningitidis*, longer intervals between doses resulted in a slightly weaker immune response (Estimates [95% CI] = -1.01% [-1.44%, -0.57%], -0.21% [-0.28%, -0.13%] for the first-to-second and second-to-third intervals, respectively).

The interval between the last vaccine dose and the immunogenicity measurement also affected the measured immune response (Figure 4). Of note, these intervals capture short time periods (1–2 months after vaccination), as the RCTs intended to measure immunogenicity consistently across individuals. For vaccines for which immunogenicity was measured after a single dose—measles, mumps, and rubella—the immune response increased over time shortly after vaccination (Estimates [95% CI] = 1.31% [1.17%, 1.45%], 0.55% [0.26%, 0.84%], and 2.15% [2.00%, 2.30%], respectively), consistent with the progressive establishment of adaptive immunity after first exposure. For vaccines for which immunogenicity was measured after primary set (two or three doses), however, longer intervals showed a slight decrease in immune response (Range of estimates [95% CI] = -1.74% [-2.33%, -1.15%], -0.87% [-1.69%, -0.06%]), reflecting the much more rapid rise and subsequent decay of the immune response after secondary exposure. The varicella vaccination showed a different pattern; despite being a primary vaccine, its immunogenicity appeared to decline as early as 6 weeks post-vaccination (Estimate [95% CI] = -1.11% [-1.51%, -0.71%]). This may reflect the different immune pathways elicited by the varicella vaccine.

Differences in vaccine formulation also contributed to variation in immune response (Figure 4). For DTP vaccines, diphtheria responses were weaker with the whole-cell vaccine than with the acellular vaccine (Range of estimates [95% CI] = -64.87% [-107.73%, -22.01%]), while tetanus responses were similar across the two vaccines. For *S. pneumoniae* serotype 4, the GSK-10 formulation produced a weaker response than the Pfizer formulations (Estimates [95% CI] = 56.06% [43.40%, 68.81%] and 30.69% [6.20%, 55.08%], for Pfizer-7 and -13, respectively), and among GSK vaccines, the GSK-10 formulation elicited a stronger immune response than GSK-11 (Estimate [95% CI] = -33.73% [-50.02%, -17.29%]),

consistent with its higher antigen concentration (Concentration = [6 µg/mL] and [2 µg/mL], respectively). Similarly, we found that the higher the vaccine concentration, the stronger the immune response against *N. meningitidis* C, varicella, and mumps (Estimates [95% CI] = 18.31% [13.19%, 23.47%], 5.29% [1.40%, 9.15%], 6.27% [1.05%, 11.55%]). In contrast, we found that the vaccine concentration was negatively associated with the immunogenicity against measles, rubella, pertussis PT, *S. pneumoniae* serotype 4, and *H. influenzae* B (Range of estimates [95% CI] = -30.22% [-38.12%, -22.52%], -4.83% [-7.02%, -2.65%]). Although these heterogeneous results in vaccine concentrations have been reported before<sup>8</sup>, this variable might be a proxy for other vaccine differences, such as adjuvant systems, vaccine lots, and formulations, which we did not explicitly account for.

Of note, we also characterized the underlying dispersion of antibody responses across individuals by estimating the shape parameter ( $\alpha$ ) of the Gamma distribution. This parameter is directly related to the coefficient of variation ( $CV = 1/\sqrt{\alpha}$ ), providing a measure of relative variability. Across the different antigens, our estimates for  $\alpha$  ranged from 1 to 3.5, which corresponds to a CV from 55.95% [54.14%, 57.97%] to 112.48% [115.73%, 114.04%] (Figure 4). This high degree of dispersion underscores the substantial inter-individual variability inherent in immunogenicity measurements, even within the controlled scheme of randomized clinical trials.

Finally, because several vaccines target multiple pathogens, serotypes, serogroups, or antigens, we examined correlations in immune responses across these components using multivariate models (Figure 4). We found that immune responses were correlated when vaccines targeted antigenically related components of the same pathogen (Range of correlations [95% CI] = 0.092 [0.055, 0.129], 0.676 [0.639, 0.709]). Correlations were less strong when vaccines targeted phylogenetically distant pathogens—for example, in multi-pathogen formulations such as MMRV, MMR, Hib–Men, DTPa, and DTPw (Range of correlations [95% CI] = 0.076 [0.052, 0.100], 0.367 [0.238, 0.486]). Together, these results show that coordinated immune responses are more likely within pathogen-specific antigenic groups than across pathogens.


Altogether, these findings demonstrate that the highly heterogeneous immune response after vaccination reflects a composite of individual, schedule-dependent, and vaccine-specific characteristics.

#### **The seasonal immune responses and their latitudinal gradients remained consistent when considering seronegative individuals in the rotavirus studies**


Given the bimodal distribution of rotavirus immunogenicity, we performed a sensitivity analysis comparing our main results, which were restricted to seronegative individuals, with models that included all participants regardless of baseline serostatus. We found that the estimated seasonal patterns, including peak amplitude and timing, remained consistent between the two approaches (Supplementary figures 11 and 12). This indicates that the observed seasonality is not an artifact of excluding baseline seropositivity but rather reflects a robust signal across the entire rotavirus vaccination cohort.

## Supplementary figures


**Sfig 1. Flowchart of study selection and participant inclusion.** Systematic selection process for the randomized clinical trials (RCTs) and participants included in the analysis.




**Sfig 2. Spatiotemporal distribution of vaccination events.** Weekly histograms show the vaccination calendar week for study participants for each pathogen, colored by latitudinal classification.





**Sfig 3. Model validation and bias assessment across pathogen-antigen subsets.** The scatter plots illustrate the mean absolute bias for peak amplitude and peak timing obtained from posterior predictive checks. To evaluate the robustness of seasonal estimates considering the temporal data gaps, datasets were simulated from the best-fitted models and refitted to assess parameter recovery. Horizontal and vertical lines represent the predefined exclusion thresholds of 20% for amplitude bias and 7 weeks for phase bias.




**Sfig 4. Comparison of seasonal model forms.** Seasonal immunogenicity patterns estimated using generalized additive models with cyclic splines (red) compared with cosine model fits (black), showing highly similar shapes with a single dominant seasonal peak. The panels show posterior conditional effects of vaccination week on immunogenicity for selected pathogens and latitudes, with curves representing posterior draws and rug marks indicating observed vaccination weeks.




**Sfig 5. Global distribution, demographic characteristics, and immunogenicity profiles of pediatric vaccination trials included in the study for sensitivity analyses with additional antigens.** A) Total number of vaccinated individuals per pathogen; color intensity indicates contributions from individual studies, and numbers denote the number of RCTs. B) Age at first vaccination, with point size proportional to the fraction of participants vaccinated at each age (months). C) Sex distribution of participants by pathogen. D) For each pathogen, weekly distribution of vaccinations across the calendar year, density of post-vaccination immunogenicity measurements, and geographic distribution of study sites (point size proportional to the number of vaccinated individuals; colors indicate latitudinal classification).



**Sfig 6. Incorporating vaccination date improves the predictive performance of vaccine immunogenicity models across pathogens and latitudes in sensitivity analyses with additional antigens.** Comparison of baseline, seasonal, and seasonal-by-latitude models for each antigen. Top panels show differences in WAIC relative to the best-fitting model ( $\Delta$ WAIC), with points indicating model variants (baseline, seasonality only, and seasonality stratified by 2–6 latitudinal groups); lower values indicate better predictive performance. The vertical grey line denotes a difference of 2 points. Bottom panels show the corresponding empirical cumulative distribution functions of observed (solid) and model-predicted (dashed) post-vaccination immunogenicity, colored by antigen. Vertical lines denote serological thresholds.




**Sfig 7. Latitudinal gradients in the seasonal timing and amplitude of the vaccine immunogenicity in sensitivity analyses with additional antigens.** Top panels show posterior estimates of seasonal amplitude (left) and peak timing (right, week of year) from the best-fitting seasonal-by-latitude models for each antigen and latitudinal group (points, medians; lines, 95% credible intervals; color indicates posterior phase density). Bottom panels show posterior conditional effects of vaccination week on immunogenicity for selected pathogens and latitudes, with curves representing posterior draws and rug marks indicating observed vaccination weeks.




**Sfig 8. Global distribution, demographic characteristics, and immunogenicity profiles of pediatric vaccination trials included in the study for sensitivity analyses with functional antibody measurements.**

A) Total number of vaccinated individuals per pathogen; color intensity indicates contributions from individual studies, and numbers denote the number of RCTs. B) Age at first vaccination, with point size proportional to the fraction of participants vaccinated at each age (months). C) Sex distribution of participants by pathogen. D) For each pathogen, weekly distribution of vaccinations across the calendar year, density of post-vaccination immunogenicity measurements, and geographic distribution of study sites (point size proportional to the number of vaccinated individuals; colors indicate latitudinal classification).




**Sfig 9. Incorporating vaccination date improves the predictive performance of vaccine immunogenicity models across pathogens and latitudes in sensitivity analyses with functional antibody measurements.**


Comparison of baseline, seasonal, and seasonal-by-latitude models for each antigen. Top panels show differences in WAIC relative to the best-fitting model ( $\Delta$ WAIC), with points indicating model variants (baseline, seasonality only, and seasonality stratified by 2–6 latitudinal groups); lower values indicate better predictive performance. The vertical grey line denotes a difference of 2 points. Bottom panels show the corresponding empirical cumulative distribution functions of observed (solid) and model-predicted (dashed) post-vaccination immunogenicity, colored by antigen. Vertical lines denote serological thresholds.




**Sfig 10. Latitudinal gradients in the seasonal timing and amplitude of the vaccine immunogenicity in sensitivity analyses with functional antibody measurements.** Top panels show posterior estimates of seasonal amplitude (left) and peak timing (right, week of year) from the best-fitting seasonal-by-latitude models for each antigen and latitudinal group (points, medians; lines, 95% credible intervals; color indicates posterior phase density). Bottom panels show posterior conditional effects of vaccination week on immunogenicity for selected pathogens and latitudes, with curves representing posterior draws and rug marks indicating observed vaccination weeks.




**Sfig 11. Incorporating vaccination date improves the predictive performance of vaccine immunogenicity models across pathogens and latitudes in sensitivity analyses for rotavirus studies that included seronegative individuals.** Comparison of baseline, seasonal, and seasonal-by-latitude models. The left panel shows differences in WAIC relative to the best-fitting model ( $\Delta$ WAIC), with points indicating model variants (baseline, seasonality only, and seasonality stratified by 2–6 latitudinal groups); lower values indicate better predictive performance. The vertical grey line denotes a difference of 2 points. The right panel shows the corresponding empirical cumulative distribution functions of observed (solid) and model-predicted (dashed) post-vaccination immunogenicity, colored by antigen. The vertical grey line denotes serological thresholds.



**Sfig 12. Latitudinal gradients in the seasonal timing and amplitude of the vaccine immunogenicity in sensitivity analyses for rotavirus studies that included seronegative individuals.** Top panels show posterior estimates of seasonal amplitude (left) and peak timing (right, week of year) from the best-fitting seasonal-by-latitude models for each model (points, medians; lines, 95% credible intervals; color indicates posterior phase density). Bottom panels show posterior conditional effects of vaccination week on immunogenicity for selected pathogens and latitudes, with curves representing posterior draws and rug marks indicating observed vaccination weeks.



**Sfig 13. Incorporating the date of birth did not outperform models that included the date of vaccination across pathogens.** Comparison of seasonal and seasonal-by-latitude models with date of birth with the best model with date of vaccination. The panels show differences in WAIC relative to the best-fitting model, with points indicating model variants (seasonality only and seasonality stratified by 2–6 latitudinal groups); lower values indicate better predictive performance. The vertical grey line denotes a difference of 2 points.



ΔWAIC from best model

## Supplementary tables

**Stable 1 Randomized controlled trials included in the study evaluating vaccine immunogenicity.** The table details the specific inclusion status of each study; "Partial exclusion" indicates that while the study was included in the broader analysis, data for specific antigens were excluded.

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
811936-001	Phase 2, open, randomized, controlled study to demonstrate the non-inferiority of the meningococcal serogroup C immune response and the superiority of the Hib immune response of GSK Biologicals' Haemophilus influenzae type b-meningococcal C-TT conjugate vaccine administered with Infanrix™ penta versus Meningitec™ administered with Infanrix™	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
217744-078	An open, multicentre, phase IV clinical trial to assess the immunogenicity and reactogenicity of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine, when co-administered at 3-4-5 Mth of age with Wyeth-Lederle's seven-valent pneumococcal conjugate vaccine at a different injection site during the same visit	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Pertussis-a (FHA, PRN, PT), Sp (04, 06b, 09v, 14, 18c, 19f, 23f), Tetanus
217744-070	An open clinical study to assess the immunogenicity and safety of GSK Bio's DTPa-HBV-IPV vaccine mixed in one syringe with Hib vaccine, as a primary vaccination course to pre-term infants(<37 weeks) at 2, 4 and 6 months of age in comparison with infants born after normal gestation period	<a href="http://clinicaltrials.gov/show/NCT00366366">http://clinicaltrials.gov/show/NCT00366366</a>	Partial exclusion of RCT group	Pre-term babies RCT group	Diphtheria, HBV, HiB, IPV (1, 2, 3), Pertussis-a (FHA, PRN, PT), Tetanus
208108-091	A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals' Tritanrix™-HepB/Hib2.5 to GSK Biologicals' Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects	<a href="http://clinicaltrials.gov/show/NCT01061541">http://clinicaltrials.gov/show/NCT01061541</a>	Partial exclusion for Polio	No Ab (Polio) No primary (Polio)	Diphtheria, HBV, HiB, Pertussis-w (PT), Tetanus
101222	Study to demonstrate the non-inferiority of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine compared to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine and to separate administration of DTPw-HBV Kft. and Hiberix™ vaccines with respect to the immunogenicity of all antigens, when administered to healthy infants.	NA	Partial exclusion for Tetanus and HiB	No Ab baseline (Tetanus, HiB)	Diphtheria, HBV, Pertussis-w (PT)
103974	Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 months and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 months	<a href="http://clinicaltrials.gov/show/NCT00258700">http://clinicaltrials.gov/show/NCT00258700</a>	Included	Included	Diphtheria, HiB, IPV (1, 2, 3), Measles, Nmen (C), Mumps, Pertussis-a (FHA, PRN, PT), Rubella, Tetanus
101858	Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years	<a href="http://clinicaltrials.gov/show/NCT00129129">http://clinicaltrials.gov/show/NCT00129129</a>	Partial exclusion for HBV	No primary (HBV)	Diphtheria, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Sp (04, 06b, 09v, 14, 18c, 19f, 23f), Tetanus
113994	Safety, reactogenicity & immunogenicity of GSK Biologicals' pneumococcal vaccine 2189242A when co-administered with DTPa-HBV-IPV/Hib vaccine in healthy infants	<a href="http://clinicaltrials.gov/show/NCT01204658">http://clinicaltrials.gov/show/NCT01204658</a>	Partial exclusion for HBV	No primary (HBV)	Diphtheria, HiB, IPV (1, 2, 3), Pertussis-a (FHA, PRN, PT), Sp (01, 03, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f), Tetanus
347414-023	A phase II, single-blind, randomized, controlled study to evaluate the immunogenicity and safety of four different formulations of an investigational vaccination regimen when given intramuscularly as primary vaccination in infants at 3, 4 ½ and 6 months of age.	NA	Included	Included	Diphtheria, HiB, IPV (1, 2, 3), Pertussis-a (FHA, PRN, PT), Sp (01, 03, 04, 05, 06b, 07f, 09v, 14, 18c, 19f, 23f), Tetanus

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
217744-085	A phase III, open labeled, randomized, multicenter, clinical study of the safety and immunogenicity of a primary series of GlaxoSmithKline Biologicals' (GSK Biologicals') DTaP-HepBIPV candidate vaccine coadministered with HibTITER® and Prevnar® to healthy infants at 2, 4, and 6 months of age as compared to the separate administration of Infanrix® + Engerix-B® + IPOL® + HibTITER + Prevnar and to GSK Biologicals' DTaP-HepB-IPV candidate vaccine coadministered with HibTITER	NA	Partial exclusion for HBV	No primary (HBV)	Diphtheria, HiB, IPV (1, 2, 3), Pertussis-a (FHA, PRN, PT), Sp (04, 06b, 09v, 14, 18c, 19f, 23f), Tetanus
114260	Immunogenicity and safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix™-IPV+Hib) vaccine in healthy Korean infants	<a href="http://clinicaltrials.gov/show/NCT01309646">http://clinicaltrials.gov/show/NCT01309646</a>	Partial exclusion for Rotavirus and Sp	No Ab (Rotavirus, Sp)	Diphtheria, HiB, IPV (1, 2, 3), Pertussis-a (FHA, PRN, PT), Tetanus
105553	Assess lot-to-lot consistency of 3 lots (double blind design) of GlaxoSmithKline Biologicals' 10-valent pneumococcal vaccine and evaluate non-inferiority to Prevnar™ (single blind design) when administered as 3-dose primary immunization course before 6 months of age	<a href="http://clinicaltrials.gov/show/NCT00307554">http://clinicaltrials.gov/show/NCT00307554</a>	Partial exclusion for HBV and Polio	No primary routine (HBV), No Ab baseline (Polio)	Diphtheria, HiB, Measles, Mumps, Pertussis-a (FHA, PRN, PT), Rubella, Sp (01, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f), Tetanus, VZV
759346-001	A phase II, open, randomized, controlled study to evaluate the immunogenicity of investigational vaccination regimens administered as a three dose primary vaccination course at 6, 10 and 14 weeks of age.	NA	Partial exclusion for HBV	No primary (HBV)	Diphtheria, HiB, Nmen (A, C), Pertussis-w (PT), Tetanus
104733	Demonstrate lot-to-lot consistency of final production method of GSK Biologicals' Hib-MenAC vaccine mixed extemporaneously with Tritanrix™-HepB & demonstrate its non-inferiority vs Tritanrix™-HepB/Hiberix™ in healthy infants at 2, 4 and 6 months	<a href="http://clinicaltrials.gov/show/NCT00197275">http://clinicaltrials.gov/show/NCT00197275</a>	Partial exclusion for HBV and Polio	No Ab baseline (HBV, Polio)	Diphtheria, HiB, Nmen (A, C), Pertussis-w (PT), Tetanus
347414-017	A multinational, randomised, controlled, single-blind, phase-II study to evaluate the safety and immunogenicity of two investigational vaccination regimens versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix) given concomitantly with DTPw-HBV vaccine in a separate injection of DTPw-HBV to infants at 2, 4, and 6 months of age	NA	Partial exclusion for HBV	No primary (HBV)	Diphtheria, HiB, Nmen (C), Pertussis-w (PT), Sp (01, 03, 04, 05, 06b, 07f, 09v, 14, 18c, 19f, 23f), Tetanus
107017	Multicentre study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant administration of GSK Biologicals' 10-valent pneumococcal conjugate, Infanrix hexa and Rotarix vaccines	<a href="http://clinicaltrials.gov/show/NCT00370318">http://clinicaltrials.gov/show/NCT00370318</a>	Partial exclusion for HBV and Polio	No primary (HBV), No Ab baseline (Polio)	Diphtheria, HiB, Pertussis-a (FHA, PRN, PT), Rotavirus, Sp (01, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f), Tetanus
106208	To assess reactogenicity and immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine, when co-administered with GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) at 2, 4 and 6 months of age.	<a href="http://clinicaltrials.gov/show/NCT00338351">http://clinicaltrials.gov/show/NCT00338351</a>	Partial exclusion for HBV and Polio	No Ab baseline (HBV, polio)	Diphtheria, HiB, Pertussis-a (FHA, PRN, PT), Sp (01, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f), Tetanus
112921	Impact of immediate or delayed prophylactic antipyretic treatment on the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals' pneumococcal vaccine 1024850A and the co-administered DTPa-combined vaccines	<a href="http://clinicaltrials.gov/show/NCT01235949">http://clinicaltrials.gov/show/NCT01235949</a>	Partial exclusion for HBV and Polio	No primary (HBV), No Ab baseline (Polio)	Diphtheria, HiB, Pertussis-a (FHA, PRN, PT), Sp (01, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f), Tetanus
105554	Phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunization course before 6 months of age	<a href="http://clinicaltrials.gov/show/NCT00307541">http://clinicaltrials.gov/show/NCT00307541</a>	Partial exclusion for HBV and Polio	No Ab baseline (HBV, Polio)	Diphtheria, HiB, Pertussis-a (FHA, PRN, PT), Sp (01, 04, 05, 06b, 07f, 09v, 14, 18c, 19f, 23f), Tetanus
107007	To assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevnar™, co-administered with DTPw-HBV/Hib & OPV or IPV vaccines as a 3-dose primary immunization course during the first 6 months of age	<a href="http://clinicaltrials.gov/show/NCT00344318">http://clinicaltrials.gov/show/NCT00344318</a>	Partial exclusion for HBV and Polio	No primary (HBV), No Ab baseline (Polio)	Diphtheria, HiB, Pertussis-w (PT), Sp (01, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f), Tetanus
104871	A multicentric study to compare the immunogenicity, safety & reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs. co-administration of GSK's DTPa vaccine & Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children	<a href="http://clinicaltrials.gov/show/NCT00290342">http://clinicaltrials.gov/show/NCT00290342</a>	Included	Included	Diphtheria, IPV (1, 2, 3), Pertussis-a (FHA, PRN, PT), Tetanus
106786	A study to evaluate the immunogenicity and safety of a new formulation of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine as compared to the currently licensed Infanrix hexa in healthy infants (2,3,4 M)	<a href="http://clinicaltrials.gov/show/NCT00376779">http://clinicaltrials.gov/show/NCT00376779</a>	Partial exclusion for HBV, HiB, and Polio	No Ab baseline (HBV, HiB, polio)	Diphtheria, Pertussis-a (FHA, PRN, PT), Tetanus

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
201330	Immunogenicity and safety study of GSK Biologicals' combined diphtheria-Tetanus-acellular pertussis-hepatitis B-inactivated polio-virus and Haemophilus influenzae type b vaccine (Infanrix hexa™) (217744) in healthy infants born to mothers vaccinated with Boostrix™ during pregnancy or immediately post-delivery	<a href="http://clinicaltrials.gov/show/NCT02422264">http://clinicaltrials.gov/show/NCT02422264</a>	Partial exclusion for HBV, HiB, Polio, and Sp	No Ab baseline (HBV, HiB, Polio, Sp)	Diphtheria, Pertussis-a (FHA, PRN, PT), Tetanus
101197	An open, multicentric, phase IV clinical trial to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals' combined diphtheria-Tetanus-acellular pertussis vaccine (Infanrix™) administered to healthy infants at 2, 4 and 6 months of age.	NA	Included	Included	Diphtheria, Pertussis-a (FHA, PRN, PT), Tetanus
104021	A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals' Tritanrix™-HepB and GSK Biologicals Kft's DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory's (CSL's) DTPw (Triple Antigen™) and GSK Biologicals' HBV (Engerix™-B), when co-administered with GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine.	<a href="http://clinicaltrials.gov/show/NCT00158756">http://clinicaltrials.gov/show/NCT00158756</a>	Partial exclusion for Polio	No Ab baseline (Polio)	Diphtheria, Pertussis-w (PT), Rotavirus, Tetanus
114056	Immunogenicity, safety and reactogenicity of GSK Biologicals' pneumococcal vaccine 1024850A when administered to children between 8 weeks and 2 years of age	<a href="http://clinicaltrials.gov/show/NCT01175083">http://clinicaltrials.gov/show/NCT01175083</a>	Partial exclusion for HBV, HiB, and Polio, Partial exclusion for RCT group	No Ab (HBV, HiB, Polio) Sickle cell babies RCT group	Diphtheria, Pertussis-w (PT), Sp (01, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f), Tetanus
115648	Consistency study of GSK Biologicals' measles-mumps-rubella (MMR) vaccine (209762) (Priorix) comparing immunogenicity and safety to Merck & Co., Inc.'s MMR vaccine (M-M-R II), in healthy children 12 to 15 months of age	<a href="http://clinicaltrials.gov/show/NCT01702428">http://clinicaltrials.gov/show/NCT01702428</a>	Partial exclusion for Mumps, Sp and VZV	No Ab method (VZV) No Ab method (Mumps), No primary (Sp)	HAV, Measles, Rubella
105910	Compare immunogenicity & reactogenicity of 2 formulations of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (new vs current) given in healthy infants. The DTPa-HBV-IPV vaccine (new formulation) will also be assessed in a 3rd group of subjects	<a href="http://clinicaltrials.gov/show/NCT00320463">http://clinicaltrials.gov/show/NCT00320463</a>	Partial exclusion for Diphtheria, Tetanus, HiB, and Polio	No Ab baseline (Diphtheria, Tetanus, HiB, polio)	HBV, Pertussis-a (FHA, PRN, PT)
759346-007	Demonstrate non-inferiority of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ with respect to anti-HBs immune response, when given to healthy infants at 6, 10 & 14 weeks age, after a birth dose of hepatitis B vaccine	<a href="http://clinicaltrials.gov/show/NCT00317122">http://clinicaltrials.gov/show/NCT00317122</a>	Partial exclusion for Diphtheria and Tetanus	No Ab baseline (Diphtheria, Tetanus)	HiB, Nmen (A, C), Pertussis-w (PT)
100480	Study to show lot-to-lot consistency of Hib-MenAC mixed with Tritanrix™-HBV, its non-inferiority to Tritanrix™-HBV/Hiberix™ with or without Meningitec™, and MenA response in 2, 4, 6 month infants with hepatitis B birth dose	<a href="http://clinicaltrials.gov/show/NCT00317161">http://clinicaltrials.gov/show/NCT00317161</a>	Partial exclusion for Diphtheria, Tetanus, and HBV	No Ab baseline (Diphtheria, Tetanus, HBV)	HiB, Nmen (A, C), Pertussis-w (PT)
100478	Study to show non-inferiority of Tritanrix™-HepB/Hib-MenAC (+/- hepatitis B vaccine at birth) versus Tritanrix™-HepB/Hiberix™ without hepatitis B vacc. at birth for antibody response to all vaccine antigens given in healthy infants	<a href="http://clinicaltrials.gov/show/NCT00290303">http://clinicaltrials.gov/show/NCT00290303</a>	Partial exclusion for Diphtheria, Tetanus, HBV, and Polio	No Ab baseline (Diphtheria, Tetanus, HBV, Polio)	HiB, Nmen (A, C), Pertussis-w (PT)
110215	Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months	<a href="http://clinicaltrials.gov/show/NCT00586612">http://clinicaltrials.gov/show/NCT00586612</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, Polio, and Sp Partial exclusion for RCT group	No Ab (Diphtheria, Tetanus, Pertussis, Polio, Sp) No primary (HBV) Pre-term babies RCT group	HiB, Nmen (C)
112157	Immunogenicity and safety study of GlaxoSmithKline Biologicals' GSK2202083A vaccine in healthy infants at 2, 3 and 4 months of age	<a href="http://clinicaltrials.gov/show/NCT00970307">http://clinicaltrials.gov/show/NCT00970307</a>	Partial exclusion for Diphtheria, Tetanus, HBV,	No Ab (rota), No Ab baseline (Diphtheria,	HiB, Nmen (C), Pertussis-a (FHA, PRN, PT)

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
			Polio, Rotavirus, and Sp	Tetanus, HBV, Polio, Sp)	
792014-003	A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of three different formulations of GSK Biologicals' combined Haemophilus influenzae type b-meningococcal serogroups C and Y- conjugate vaccine and one formulation of GSK Biologicals' Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine each given concomitantly with InfanrixTM penta, versus MeningitecTM, given concomitantly with InfanrixTM hexa in infants according to a 2-3-4 month schedule	<a href="http://clinicaltrials.gov/show/NCT00129116">http://clinicaltrials.gov/show/NCT00129116</a>	Partial exclusion for Diphtheria, HBV, and Polio	No Ab baseline (Diphtheria, HBV, Polio)	HiB, Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
112679	Immunogenicity and safety of GSK Biologicals' IPV (Polarix™) in infants	<a href="http://clinicaltrials.gov/show/NCT01021293">http://clinicaltrials.gov/show/NCT01021293</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HiB, and Polio	No Ab (Diphtheria, Tetanus, Pertussis, HiB), No Ab baseline (Polio)	IPV1, IPV2, IPV3
111157	Immunogenicity and safety study of GlaxoSmithKline Biologicals' Infanrix hexa™ vaccine in healthy infants in India	<a href="http://clinicaltrials.gov/show/NCT01353703">http://clinicaltrials.gov/show/NCT01353703</a>	Partial exclusion for Diphtheria, Tetanus, and HiB	No Ab baseline (Diphtheria, Tetanus, HiB)	IPV (1, 2, 3), Pertussis-a (FHA, PRN, PT)
759348-001	A randomised, controlled phase II study to evaluate the safety and immunogenicity of 7 different formulations of GSK Biologicals' investigational vaccination regimen, when administered as a 3-dose primary immunisation schedule before 6 months of age, followed by a fourth dose during the second year of life	NA	Partial exclusion for Diphtheria, Tetanus, HBV, HiB, and Nmen	No Ab baseline (Diphtheria, Tetanus, HBV, HiB, Nmen)	IPV (1, 2, 3), Pertussis-a (FHA, PRN, PT), Sp (01, 03, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f)
347414-029	Multinational, randomised, controlled, open, phase 2 clinical study to evaluate the safety and immunogenicity of GSK Biologicals' investigational vaccination regimen administered as a booster dose to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study 347414/017	NA	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, and Sp	No primary (Diphtheria, Tetanus, Pertussis, HBV, HiB, Sp)	Measles, Mumps, Rubella
115555	Immunogenicity and safety study of GlaxoSmithKline Biological's live attenuated measles mumps rubella varicella vaccine (PriorixTetra™) when co-administered with conjugated Meningococcal C vaccine (Meningitec®, Nuron Biotech's Vaccine) in healthy children	<a href="http://clinicaltrials.gov/show/NCT01506193">http://clinicaltrials.gov/show/NCT01506193</a>	Partial exclusion for Nmen and VZV	No Ab method (VZV), No Ab baseline (Nmen)	Measles, Mumps, Rubella
209762-147	Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK)Biologicals live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18months in Singapore.	<a href="http://clinicaltrials.gov/show/NCT00388440">http://clinicaltrials.gov/show/NCT00388440</a>	Partial exclusion for VZV	No Ab (VZV)	Measles, Mumps, Rubella
209762-151	Phase II study to evaluate immunogenicity, reactogenicity and safety of GSK Bios' investigational vaccination regimen compared to the currently licensed GSK Bios' Priorix™ and Merck and Co.'s M-M-R@II vaccines when administered as a primary vaccination to healthy children aged 12-24 months	NA	Included	Included	Measles, Mumps, Rubella
208136-013	Study to assess immunogenicity and safety of one dose of GSK Bios' live attenuated MMRV vaccine, co-admin with a booster dose of the GSK Bios' combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine	NA	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, and Polio	No primary routine (Diphtheria, Tetanus, Pertussis, HBV, HiB, Polio)	Measles, Mumps, Rubella, VZV
110876	Immunogenicity & safety study of GSK Biologicals' combined measles-mumps-rubella-varicella vaccine 208136	<a href="http://clinicaltrials.gov/show/NCT00751348">http://clinicaltrials.gov/show/NCT00751348</a>	Included	Included	Measles, Mumps, Rubella, VZV
109995	A phase IIb, open, randomised, multicentre, primary study in healthy children, to establish the non-inferiority of GlaxoSmithKline (GSK) Biologicals' MeMuRu-OKA vaccine (administered at 9 and 15 months of age) versus Priorix™ (9 months of age) and Priorix™ co-administered with Varilrix™ at 15 months of age (comparator) and also to evaluate the	<a href="http://clinicaltrials.gov/show/NCT00969436">http://clinicaltrials.gov/show/NCT00969436</a>	Included	Included	Measles, Mumps, Rubella, VZV

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
	non-inferiority of Priorix™ (9 months of age) and MeMuRu-OKA vaccine (15 months of age) versus the comparator, all administered subcutaneously as two-dose primary vaccination course				
103388	Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life	<a href="http://clinicaltrials.gov/show/NCT00127010">http://clinicaltrials.gov/show/NCT00127010</a>	Included	Included	Measles, Mumps, Rubella, VZV
104020	Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life	<a href="http://clinicaltrials.gov/show/NCT00126997">http://clinicaltrials.gov/show/NCT00126997</a>	Included	Included	Measles, Mumps, Rubella, VZV
104389	Blinded, randomised, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' combined measles-mumps-rubella-varicella candidate vaccine given to healthy children in their second year of life	<a href="http://clinicaltrials.gov/show/NCT00127023">http://clinicaltrials.gov/show/NCT00127023</a>	Included	Included	Measles, Mumps, Rubella, VZV
108760	Immunogenicity & safety study of GSK Biologicals' 208136 vaccine formulated with new measles and rubella working seeds	<a href="http://clinicaltrials.gov/show/NCT00892775">http://clinicaltrials.gov/show/NCT00892775</a>	Included	Included	Measles, Mumps, Rubella, VZV
208136-038	Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' Priorix™ and Varilrix™ vaccines	NA	Included	Included	Measles, Mumps, Rubella, VZV
100388	Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (Varilrix™) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine	<a href="http://clinicaltrials.gov/show/NCT00226499">http://clinicaltrials.gov/show/NCT00226499</a>	Included	Included	Measles, Mumps, Rubella, VZV
209762-136	A phase III, blinded, randomized, multicenter U.S. study evaluating the clinical consistency of three production lots of SmithKline Beecham Biologicals' MMR vaccine (PRIORIX) and comparability of PRIORIX with Merck's M-M-R II vaccine, administered to healthy children 12 to 18 months of age	NA	Included	Included	Measles, Mumps, Rubella, VZV
209762-148	Phase II, double blind, randomized sequential study to compare immunogenicity and reactogenicity of the current formulations of GSK Bios' measles-mumps-rubella vaccine and GSK Bios' varicella vaccine containing human serum albumin with the modified formulations which do not contain HSA	NA	Included	Included	Measles, Mumps, Rubella, VZV
208136-006	Study evaluating in healthy children safety and immunogenicity of GSK Bios' combined Measles-Mumps-Rubella-Varicella vaccine, compared to GSK Bios' Varicella and Measles-Mumps-Rubella vaccines admin'd as separate injections	NA	Included	Included	Measles, Mumps, Rubella, VZV
208136-018	Study to evaluate immunogenicity and safety of GSK Bios' MeMuRu-OKA vaccine compared to concomitant administrations of GSK Bios' Priorix™ and Varilrix™ vaccines	NA	Included	Included	Measles, Mumps, Rubella, VZV
208136-007	Study to assess consistency of 3 production lots of GSK Bios' combined measles-mumps-rubella-varicella vaccine in terms of immunogenicity and safety, compared to administration of GSK Bios' measles-mumps-rubella vaccine and varicella vaccine in healthy children in their second year of life	NA	Included	Included	Measles, Mumps, Rubella, VZV
208136-016	Study to assess immunogenicity and safety of two lots of GSK Bios' live attenuated measles-mumps-rubella-varicella vaccine, at two different titres, given as a single injection to healthy children with GSK Bios' measles-mumps-rubella vaccine as control group	NA	Included	Included	Measles, Mumps, Rubella, VZV
115649	Immunogenicity and safety study of GSK Biologicals' Priorix vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.'s measles-mumps-rubella (MMR) vaccine when both are given on a 2-dose schedule to healthy children in their 2nd year of life	<a href="http://clinicaltrials.gov/show/NCT01681992">http://clinicaltrials.gov/show/NCT01681992</a>	Partial exclusion for HAV, Mumps, Sp, and VZV	No Ab HAV, Sp, VZV), No Ab method (Mumps), No primary (Sp)	Measles, rubel
115650	Safety and immunogenicity study of GSK Biologicals' measles-mumps-rubella (MMR) vaccine (209762) comparing immunogenicity and safety to Merck & Co., Inc.'s MMR vaccine, in healthy children 12 to 15 months of age	<a href="http://clinicaltrials.gov/show/NCT02184572">http://clinicaltrials.gov/show/NCT02184572</a>	Partial exclusion for HAV, Mumps, Sp, and VZV	No Ab (HAV, Sp VZV),	Measles, rubel

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
				No Ab method (Mumps), No primary (Sp)	
217744-097	Study to assess immunogenicity and reactogenicity of three doses of GSK Bio's combined Hib-MenC vaccine co-admin with GSK Bio's DTPa-HBV-IPV vaccine and of two doses of Baxters meningococcal C conjugate vaccine co-admin with GSK Bio's DTPa-HBV-IPV/Hib vaccine	<a href="http://clinicaltrials.gov/show/NCT00352963">http://clinicaltrials.gov/show/NCT00352963</a>	Partial exclusion for Diphtheria, Tetanus, HBV, HiB, and Polio	No Ab baseline (Diphtheria, Tetanus, HBV, HiB, Polio)	Nmen (C), Pertussis-a (FHA, PRN, PT)
103488	A randomized, controlled, phase II study to evaluate the safety and immunogenicity of different formulations of GlaxoSmithKline Biologicals' 11-valent pneumococcal conjugate vaccine, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age	<a href="http://clinicaltrials.gov/show/NCT00169481">http://clinicaltrials.gov/show/NCT00169481</a>	Partial exclusion for Diphtheria, Tetanus, HBV, HiB, and Polio	No Ab baseline (Diphtheria, Tetanus, HBV, HiB, Polio)	Pertussis-a (FHA, PRN, PT), Sp (01, 03, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f)
759348-007	A randomized, controlled, phase II study to evaluate the safety and immunogenicity of five formulations of GlaxoSmithKline Biologicals' investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization schedule (2-3-4 month schedule) before 6 months of age.	NA	Partial exclusion for Diphtheria, Tetanus, HBV, HiB, and Polio	No Ab baseline (Diphtheria, Tetanus, HBV, HiB, Polio)	Pertussis-a (FHA, PRN, PT), Sp (01, 03, 04, 05, 06b, 07f, 09v, 14, 18c, 19f, 23f)
104489	Study to assess immunogenicity and safety of GlaxoSmithKline Biologicals' Kft's DTPw-HBV/Hib vs DTPwCSL-HBV/Hib Kft and vs concomitant administration of CSL's Triple Antigen and GlaxoSmithKline Biologicals' Hiberix, to infants at 2, 4, 6 months of age, after a birth dose of hepatitis B	<a href="http://clinicaltrials.gov/show/NCT00316680">http://clinicaltrials.gov/show/NCT00316680</a>	Partial exclusion for Diphtheria, Tetanus, HBV, and HiB	No Ab baseline (Diphtheria, Tetanus, HBV, HiB)	Pertussis-w (PT)
101223	Study to assess the lot-to-lot consistency of the production method of GSK Biologicals' DTPw-HBV/ Hib Kft. vaccine and to compare to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine, when administered as a primary vaccination course.	NA	Partial exclusion for Diphtheria, Tetanus, HBV, HiB, and Polio	No Ab (Polio), No Ab baseline (Diphtheria, Tetanus, HBV, HiB)	Pertussis-w (PT)
113808	Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in healthy infants	<a href="http://clinicaltrials.gov/show/NCT01171963">http://clinicaltrials.gov/show/NCT01171963</a>	Partial exclusion for Diphtheria, Tetanus, and Pertussis	No Ab method (Diphtheria, Tetanus, Pertussis)	Rotavirus
444563-021	Phase II, double-blind, randomized, placebo-controlled clinical study to assess immunogenicity and reactogenicity of doses of a modified vaccine formulation versus GSK Biologicals' live attenuated human rotavirus vaccine when orally administered to healthy infants at 2, 4 and 6 months of age	NA	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB	No Ab (Diphtheria, Tetanus, Pertussis, HBV, HiB)	Rotavirus
115461	Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals' human rotavirus (HRV) vaccine (444563), in healthy infants starting at age 6-12 weeks	<a href="http://clinicaltrials.gov/show/NCT02914184">http://clinicaltrials.gov/show/NCT02914184</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, Nmen, Polio, and Sp	No Ab (Diphtheria, Tetanus, Pertussis, HBV, HiB, Nmen, Polio, Sp)	Rotavirus
102247	A multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines	<a href="http://clinicaltrials.gov/show/NCT00140686">http://clinicaltrials.gov/show/NCT00140686</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, Nmen, Polio, and Sp	No Ab baseline (Diphtheria, Tetanus, Pertussis, HBV, HiB, Nmen, Polio, Sp)	Rotavirus

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
106260	A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.	<a href="http://clinicaltrials.gov/show/NCT00396630">http://clinicaltrials.gov/show/NCT00396630</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, and Polio	No Ab (Diphtheria, Tetanus, Pertussis, HBV, HiB, Polio)	Rotavirus
107077	A study to assess the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals' live attenuated HRV vaccine, given as a two-dose primary vaccination, in healthy infants previously uninfected with HRV	<a href="http://clinicaltrials.gov/show/NCT00363545">http://clinicaltrials.gov/show/NCT00363545</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, and Polio	No Ab (Diphtheria, Tetanus, Pertussis, HBV, HiB, Polio)	Rotavirus
107876	Study to evaluate clinical consistency of the liquid formulation of GSK Biologicals' HRV vaccine and to evaluate liquid formulation compared to lyophilised formulation of the HRV vaccine administered as a two-dose primary vaccination.	<a href="http://clinicaltrials.gov/show/NCT00382772">http://clinicaltrials.gov/show/NCT00382772</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, and Polio	No Ab (Diphtheria, Tetanus, Pertussis, HBV, HiB, Polio)	Rotavirus
444563-020	Phase II, double-blind randomised, placebo controlled clinical dose-range study to assess immunogenicity and reactogenicity of an investigational vaccination regimen, and to assess immunogenicity of OPV orally co-administered to healthy infants at 2, 4 and 6 months of age	NA	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, and Polio	No Ab baseline (Diphtheria, Tetanus, Pertussis, HBV, HiB, Polio)	Rotavirus
444563-005	Phase II, double-blind, randomized, placebo-controlled study of 2 doses of GSK Bios' live attenuated human rotavirus vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants following a 0, 2 month schedule and previously uninfected with human rotavirus	<a href="http://clinicaltrials.gov/show/NCT00729001">http://clinicaltrials.gov/show/NCT00729001</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, Nmen, Polio, and Sp	No Ab (HBV, Nmen), No Ab baseline (Diphtheria, Tetanus, Pertussis, Polio, Sp)	Rotavirus
103992	Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals' oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh	<a href="http://clinicaltrials.gov/show/NCT00139334">http://clinicaltrials.gov/show/NCT00139334</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, and Polio	No Ab (Diphtheria, Tetanus, Pertussis, HBV), No primary (Polio)	Rotavirus
105722	A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam	<a href="http://clinicaltrials.gov/show/NCT00345956">http://clinicaltrials.gov/show/NCT00345956</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, and Polio	No Ab (Diphtheria, Tetanus, Pertussis, HBV, Polio)	Rotavirus
444563-014	Study of safety, reactogenicity and immunogenicity of two doses of GSK Bio's oral live attenuated human rotavirus vaccine co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants in South Africa	<a href="http://clinicaltrials.gov/show/NCT00346892">http://clinicaltrials.gov/show/NCT00346892</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, and Polio	No Ab (Diphtheria, Tetanus, Pertussis, HiB), No primary (Polio)	Rotavirus
444563-007	Study to assess efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Bio's oral live attenuated human rotavirus vaccine at different viral concentrations in healthy infants previously uninfected with human rotavirus and approximately 3 months of age	<a href="http://clinicaltrials.gov/show/NCT00429481">http://clinicaltrials.gov/show/NCT00429481</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, and Polio	No Ab baseline (Diphtheria, Tetanus, Pertussis, HBV, HiB, Polio)	Rotavirus

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
444563-013	A phase II, randomized, double-blind, placebo-controlled study of safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus vaccine at 10E6.5 CCID50 viral concentration in healthy infants (approximately 5-10 weeks old) in the Republic of South Africa	<a href="http://clinicaltrials.gov/show/NCT00383903">http://clinicaltrials.gov/show/NCT00383903</a>	Partial exclusion for Polio	No primary routine (Polio)	Rotavirus
444563-003	A phase II, double-blind, randomized, placebo-controlled, dose-escalating, stepwise study to assess safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' live attenuated human rotavirus (HRV) vaccine in healthy infants previously uninfected with human rotavirus.	NA	Partial exclusion for RCT group	Placebo RCT group	Rotavirus
109216	Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants.	<a href="http://clinicaltrials.gov/show/NCT00432380">http://clinicaltrials.gov/show/NCT00432380</a>	Included	Included	Rotavirus
112269	Immunogenicity, reactogenicity and safety study to evaluate two doses of the lyophilised formulation of the human rotavirus (HRV) vaccine when administered to healthy Korean infants previously uninfected with HRV	<a href="http://clinicaltrials.gov/show/NCT00969228">http://clinicaltrials.gov/show/NCT00969228</a>	Included	Included	Rotavirus
113518	Reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine 444563, in healthy infants	<a href="http://clinicaltrials.gov/show/NCT01107587">http://clinicaltrials.gov/show/NCT01107587</a>	Included	Included	Rotavirus
101555	A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals' live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV	NA	Included	Included	Rotavirus
444563-033	Study to assess the clinical consistency of three production lots of GSK Biologicals' HRV vaccine in terms of immunogenicity and safety when given to healthy infants at 2 and 4 months of age	<a href="http://clinicaltrials.gov/show/NCT00757770">http://clinicaltrials.gov/show/NCT00757770</a>	Included	Included	Rotavirus
102248	Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants	<a href="http://clinicaltrials.gov/show/NCT00241644">http://clinicaltrials.gov/show/NCT00241644</a>	Included	Included	Rotavirus
103477	Study to assess the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals' oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus	<a href="http://clinicaltrials.gov/show/NCT00169455">http://clinicaltrials.gov/show/NCT00169455</a>	Included	Included	Rotavirus
103478	Assess the immunogenicity, safety & reactogenicity of 2 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus	<a href="http://clinicaltrials.gov/show/NCT00134732">http://clinicaltrials.gov/show/NCT00134732</a>	Included	Included	Rotavirus
104480	Compare the immunogenicity, reactogenicity & safety of 2 different formulations of GSK Biologicals' live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV	<a href="http://clinicaltrials.gov/show/NCT00137930">http://clinicaltrials.gov/show/NCT00137930</a>	Included	Included	Rotavirus
444563-004	A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants.	<a href="http://clinicaltrials.gov/show/NCT00425737">http://clinicaltrials.gov/show/NCT00425737</a>	Included	Included	Rotavirus
114351	Immunogenicity, reactogenicity and safety study of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy Taiwanese infants who received hepatitis B immunoglobulin after birth.	<a href="http://clinicaltrials.gov/show/NCT01198769">http://clinicaltrials.gov/show/NCT01198769</a>	Included	Included	Rotavirus
111634	Primary and booster vaccination course in human immunodeficiency virus (HIV) infected infants, HIV exposed uninfected infants and unexposed uninfected infants receiving the pneumococcal vaccine GSK 1024850A.	<a href="http://clinicaltrials.gov/show/NCT00829010">http://clinicaltrials.gov/show/NCT00829010</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, Measles, and Polio,	No vaccine concentration (Measles), No Ab baseline (Diphtheria, Tetanus, Pertussis, HBV, HiB, Polio),	Rotavirus, Sp (01, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f)

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
			Partial exclusion for RCT group	HIV+ babies RCT group	
110521	Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A co-administered with Zilbrix™ Hib and Polio Sabin™	<a href="http://clinicaltrials.gov/show/NCT00678301">http://clinicaltrials.gov/show/NCT00678301</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, and Polio	No Ab (Polio), No primary (HBV), No Ab baseline (Diphtheria, Tetanus, Pertussis, HiB)	Sp (01, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f)
109861	Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A, Infanrix hexa and Rotarix	<a href="http://clinicaltrials.gov/show/NCT00533507">http://clinicaltrials.gov/show/NCT00533507</a>	Partial exclusion for Diphtheria, Tetanus, Pertussis, HBV, HiB, Polio, and Rotavirus	No Ab baseline (Diphtheria, Tetanus, Pertussis, HiB, Polio, Rotavirus), No primary (HBV)	Sp (01, 04, 05, 06a, 06b, 07f, 09v, 14, 18c, 19a, 19f, 23f)
105908	Comparative study evaluating the immunogenicity and safety of MeMuRu-OKA vaccine and measles-mumps-rubella vaccine (Priorix™) co-administered with varicella vaccine (Varilrix™) in children primed with measles-mumps-rubella vaccine	<a href="http://clinicaltrials.gov/show/NCT00353288">http://clinicaltrials.gov/show/NCT00353288</a>	Partial exclusion for Measles, Mumps, and Rubella	No primary (Measles, Mumps, Rubella)	VZV
109705	Study of two formulations of GSK Biologicals' varicella vaccine given as a 2-dose course in the second year of life	<a href="http://clinicaltrials.gov/show/NCT00568334">http://clinicaltrials.gov/show/NCT00568334</a>	Included	Included	VZV
104727	Assess immunogenicity, safety & reactogenicity of a 4th dose of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC at 15-24 m & of a dose of Mencevax™ ACWY at 24-30 m in subjects primed with 3 doses of Tritanrix™-HepB/Hib-MenAC	<a href="http://clinicaltrials.gov/show/NCT00136604">http://clinicaltrials.gov/show/NCT00136604</a>	Excluded for all	Added to 100480	NA
102015	Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years	<a href="http://clinicaltrials.gov/show/NCT00129129">http://clinicaltrials.gov/show/NCT00129129</a>	Excluded for all	Added to 101858	NA
107824	A study to evaluate the long-term antibody persistence at 1, 3 & 5 years after the administration of a fourth dose of Hib-MenCY-TT Vaccine compared to ActHIB in subjects boosted in a previous study.	<a href="http://clinicaltrials.gov/show/NCT00359983">http://clinicaltrials.gov/show/NCT00359983</a>	Excluded for all	Added to 101858	NA
104056	Study to demonstrate the non-inferiority of the meningococcal serogroup C immune response of GlaxoSmithKline Biologicals' Hib-MenC vaccine co-administered with Infanrix™-IPV versus a licensed meningococcal serogroup C vaccine co-administered with Pediacel™ vaccine	NA	Excluded for all	Added to 103974	NA
109664	Assessment of long-term antibody persistence after a booster dose of GSK Biologicals' Hib & meningococcal C vaccine (Mentorix™) 811936 given at 12-15 months of age to subjects primed with 3 doses of Mentorix™ at 2, 3, 4 months of age	<a href="http://clinicaltrials.gov/show/NCT00454987">http://clinicaltrials.gov/show/NCT00454987</a>	Excluded for all	Added to 103974	NA
111736	Vaccination course in children primed and boosted with pneumococcal vaccine GSK 1024850A and in age-matched unprimed children	<a href="http://clinicaltrials.gov/show/NCT00792909">http://clinicaltrials.gov/show/NCT00792909</a>	Excluded for all	Added to 105539	NA
106623	Multicentre immune memory study in healthy children following a 3 dose primary vaccination with Prevnar or GSK Biologicals' pneumococcal conjugate vaccine via the administration of a single booster dose of Pneumovax 23	<a href="http://clinicaltrials.gov/show/NCT00333450">http://clinicaltrials.gov/show/NCT00333450</a>	Excluded for all	Added to 105554	NA
112807	Vaccination with the pneumococcal vaccine GSK 1024850A or Prevnar™ at approximately 4 years of age in children primed with 3 doses of GSK 1024850A vaccine or Prevnar™ and boosted with 23-valent pneumococcal plain polysaccharide vaccine	<a href="http://clinicaltrials.gov/show/NCT00907777">http://clinicaltrials.gov/show/NCT00907777</a>	Excluded for all	Added to 105554	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
109507	Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines	<a href="http://clinicaltrials.gov/show/NCT00463437">http://clinicaltrials.gov/show/NCT00463437</a>	Excluded for all	Added to 107005	NA
112830	Persistence of antibodies after full vaccination course with GSK Biologicals' Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age	<a href="http://clinicaltrials.gov/show/NCT00891176">http://clinicaltrials.gov/show/NCT00891176</a>	Excluded for all	Added to 107005	NA
110217	Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months	<a href="http://clinicaltrials.gov/show/NCT00586612">http://clinicaltrials.gov/show/NCT00586612</a>	Excluded for all	Added to 110215	NA
114306	Immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals' IPV (Poliorix™) in healthy Chinese toddlers	<a href="http://clinicaltrials.gov/show/NCT01323647">http://clinicaltrials.gov/show/NCT01323647</a>	Excluded for all	Added to 112679	NA
208108-092	A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals' Tritanrix™-HepB/Hib2.5 to GSK Biologicals' Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects	<a href="http://clinicaltrials.gov/show/NCT01061541">http://clinicaltrials.gov/show/NCT01061541</a>	Excluded for all	Added to 208108-091	NA
106745	Multicentre study to assess persistence of antibodies against hepatitis B & immune response to a hepatitis B challenge dose in healthy children 4 to 6 yrs old previously vaccinated with 4 doses of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine	<a href="http://clinicaltrials.gov/show/NCT00335881">http://clinicaltrials.gov/show/NCT00335881</a>	Excluded for all	Added to 217744-078	NA
217744-081	An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of a 4th dose of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine, co-administered with Wyeth's seven-valent Pneumococcal conjugate vaccine at a different injection site during the same visit in healthy children	NA	Excluded for all	Added to 217744-078 (partially - no dates)	NA
102547	Evaluate immunogenicity,safety & reactogenicity of a booster dose of Hib-MenC conjugate vaccine when given to healthy subjects aged 13-14 months who were primed with 3 doses of Hib-MenC vs a booster dose of Infanrix hexa given to subjects primed with 3 doses of Infanrix hexa and Meningitec	<a href="http://clinicaltrials.gov/show/NCT00323050">http://clinicaltrials.gov/show/NCT00323050</a>	Excluded for all	Added to 217744-097	NA
106672	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097	<a href="http://clinicaltrials.gov/show/NCT00322335">http://clinicaltrials.gov/show/NCT00322335</a>	Excluded for all	Added to 217744-097	NA
106673	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097	<a href="http://clinicaltrials.gov/show/NCT00322335">http://clinicaltrials.gov/show/NCT00322335</a>	Excluded for all	Added to 217744-097	NA
106675	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097	<a href="http://clinicaltrials.gov/show/NCT00322335">http://clinicaltrials.gov/show/NCT00322335</a>	Excluded for all	Added to 217744-097	NA
106679	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097	<a href="http://clinicaltrials.gov/show/NCT00322335">http://clinicaltrials.gov/show/NCT00322335</a>	Excluded for all	Added to 217744-097	NA
106680	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097	<a href="http://clinicaltrials.gov/show/NCT00322335">http://clinicaltrials.gov/show/NCT00322335</a>	Excluded for all	Added to 217744-097	NA
347414-026	A Phase III, randomized single-blind clinical trial to assess the immune memory induced by an investigational vaccination regimen in comparison with Prevnar and the immune response to a fourth dose of the pneumococcal vaccine and the investigational vaccination regimen, when administered to healthy children (12-15 Months)	NA	Excluded for all	Added to 347414-020 (partially - no dates)	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
347414-036	A phase-3, open, controlled study to assess the safety and immunogenicity of four different formulations of GSK Biologicals' investigational vaccination regimen when administered as a booster to healthy infants, 12 to 16 months old, previously vaccinated in infancy in a primary study 347414/023	NA	Excluded for all	Added to 347414-023 (partially - no dates)	NA
759346-002	Assess immune persistence & memory by giving plain PRP,PSA & PSC (10 mths age), & immunogenicity & safety of a Tritanrix™-HBV/Hib-MenAC/ Tritanrix™-HBV/Hib2.5 booster (15-18 mths age) in previously primed subjects	<a href="http://clinicaltrials.gov/show/NCT00317174">http://clinicaltrials.gov/show/NCT00317174</a>	Excluded for all	Added to 759346-001	NA
792014-002	A phase II, open, randomized, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of an investigational vaccination regimen versus ActHIB® and Menjugate® given concomitantly with Infanrix® penta and Prevenar® in infants	NA	Excluded for all	Added to 792014-001	NA
100381	Study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-admin with Infanrix penta) compared to a booster dose of Menjugate (co-admin with Infanrix hexa)	NA	Excluded for all	Added to 792014-003	NA
107706	To assess safety, reactogenicity & immunogenicity of a booster dose of pneumococcal conjugate vaccine, co-admin with GSK Biologicals' MMRV vaccine in children (2nd yr of life) primed with the pneumococcal conjugate vaccine in study 105553.	<a href="http://clinicaltrials.gov/show/NCT00370227">http://clinicaltrials.gov/show/NCT00370227</a>	Excluded for all	Booster 105553	NA
107046	To assess the safety, reactogenicity & immunogenicity of a 4th dose of GSK Biologicals' pneumococcal vaccine or Prevenar™ in children (12-18 months) previously vaccinated in the primary study 105553 with either pneumococcal vaccine or Prevenar™	<a href="http://clinicaltrials.gov/show/NCT00370396">http://clinicaltrials.gov/show/NCT00370396</a>	Excluded for all	Booster 105553	NA
109509	Booster vaccination course with the pneumococcal vaccine GSK 1024850A, DTPw-HBV/Hib and OPV or IPV in children who completed the primary vaccination course in study 107007	<a href="http://clinicaltrials.gov/show/NCT00547248">http://clinicaltrials.gov/show/NCT00547248</a>	Excluded for all	Booster 107007	NA
113166	Safety, reactogenicity and immunogenicity study of GSK Biologicals' pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Malian children	<a href="http://clinicaltrials.gov/show/NCT00985465">http://clinicaltrials.gov/show/NCT00985465</a>	Excluded for all	Booster 110521	NA
113199	Safety, reactogenicity and immunogenicity study of GSK Biologicals' pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Nigerian children	<a href="http://clinicaltrials.gov/show/NCT01153893">http://clinicaltrials.gov/show/NCT01153893</a>	Excluded for all	Booster 110521	NA
105555	A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals' 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of a single dose of 23-valent plain polysaccharide vaccine in healthy children, previously vaccinated in infancy in the primary study 11PN-PD-DIT-002 (103488)	<a href="http://clinicaltrials.gov/show/NCT00307567">http://clinicaltrials.gov/show/NCT00307567</a>	Excluded for all	Contained in 103488	NA
209762-150	Double blind, randomized sequential study to compare immunogenicity and reactogenicity of current formulations of GSK Bios' measles-mumps-rubella vaccine and GSK Bios' varicella vaccine to investigational vaccination regimens	NA	Excluded for all	Contained in study 209762-148	NA
104105	Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (Varilrix™) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine	<a href="http://clinicaltrials.gov/show/NCT00226499">http://clinicaltrials.gov/show/NCT00226499</a>	Excluded for all	Follow up 100388	NA
104106	Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (Varilrix™) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine	<a href="http://clinicaltrials.gov/show/NCT00226499">http://clinicaltrials.gov/show/NCT00226499</a>	Excluded for all	Follow up 100388	NA
103494	Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (Varilrix™) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine	<a href="http://clinicaltrials.gov/show/NCT00226499">http://clinicaltrials.gov/show/NCT00226499</a>	Excluded for all	Follow up 100388	NA
105239	Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study	<a href="http://clinicaltrials.gov/show/NCT00291343">http://clinicaltrials.gov/show/NCT00291343</a>	Excluded for all	Follow up 100478	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
105245	Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study	<a href="http://clinicaltrials.gov/show/NCT00291343">http://clinicaltrials.gov/show/NCT00291343</a>	Excluded for all	Follow up 100478	NA
104065	Immune memory of GSK's DTPw-HBV/Hib vaccine by giving Plain PRP polysaccharide at 10 mths. Immuno & reacto of a booster dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 mths in infants previously primed with DTPw-HBV/Hib	<a href="http://clinicaltrials.gov/show/NCT00169442">http://clinicaltrials.gov/show/NCT00169442</a>	Excluded for all	Follow up 101222	NA
106602	Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals' DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals' DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines.	<a href="http://clinicaltrials.gov/show/NCT00332566">http://clinicaltrials.gov/show/NCT00332566</a>	Excluded for all	Follow up 101223	NA
109810	To assess long-term efficacy & safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247).	<a href="http://clinicaltrials.gov/show/NCT00420316">http://clinicaltrials.gov/show/NCT00420316</a>	Excluded for all	Follow up 102247	NA
111274	Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants	<a href="http://clinicaltrials.gov/show/NCT00241644">http://clinicaltrials.gov/show/NCT00241644</a>	Excluded for all	Follow up 102248	NA
104690	Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life	<a href="http://clinicaltrials.gov/show/NCT00127010">http://clinicaltrials.gov/show/NCT00127010</a>	Excluded for all	Follow up 103388	NA
111535	Immunogenicity and reactogenicity study of GlaxoSmithKline Biologicals' Infanrix™/Hib vaccine administered as a booster dose to 18-24 months old children	<a href="http://clinicaltrials.gov/show/NCT00696423">http://clinicaltrials.gov/show/NCT00696423</a>	Excluded for all	Follow up 104567	NA
104730	A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax™ ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727.	<a href="http://clinicaltrials.gov/show/NCT00136604">http://clinicaltrials.gov/show/NCT00136604</a>	Excluded for all	Follow up 104727	NA
110478	Immunogenicity and reactogenicity study of a new formulation of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine administered as a booster dose to 18-23 months old children	<a href="http://clinicaltrials.gov/show/NCT00611559">http://clinicaltrials.gov/show/NCT00611559</a>	Excluded for all	Follow up 105910	NA
110031	Phase II, observer-blind follow-up study to assess reacto-and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), when given as booster in primed children or as 2-dose catch-up in unprimed children.	<a href="http://clinicaltrials.gov/show/NCT00513409">http://clinicaltrials.gov/show/NCT00513409</a>	Excluded for all	Follow up 106208	NA
111344	Immunogenicity and reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine when given as a booster dose.	<a href="http://clinicaltrials.gov/show/NCT00627458">http://clinicaltrials.gov/show/NCT00627458</a>	Excluded for all	Follow up 106786	NA
107137	Prophylactic antipyretic treatment in children receiving booster dose of pneumococcal vaccine GSK1024850A and DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) and assessment of impact of pneumococcal vaccination on nasopharyngeal carriage	<a href="http://clinicaltrials.gov/show/NCT00496015">http://clinicaltrials.gov/show/NCT00496015</a>	Excluded for all	Follow up 107017	NA
111345	Long-term follow-up study to assess antibody persistence in children previously vaccinated with four doses of pneumococcal conjugate vaccine in primary vaccination study (105553) and booster vaccination study (107046)	<a href="http://clinicaltrials.gov/show/NCT00624819">http://clinicaltrials.gov/show/NCT00624819</a>	Excluded for all	Follow up 107046	NA
111346	Assessment of long-term antibody persistence and immunological memory in children previously vaccinated with four pneumococcal conjugate vaccine doses and assessment of pneumococcal catch-up vaccination with GSK1024850A at 5 years of age	<a href="http://clinicaltrials.gov/show/NCT00624819">http://clinicaltrials.gov/show/NCT00624819</a>	Excluded for all	Follow up 107046	NA
111347	Assessment of long-term antibody persistence and immunological memory in children previously vaccinated with four pneumococcal conjugate vaccine doses and assessment of pneumococcal catch-up vaccination with GSK1024850A at 5 years of age.	<a href="http://clinicaltrials.gov/show/NCT00624819">http://clinicaltrials.gov/show/NCT00624819</a>	Excluded for all	Follow up 107046	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
112801	Vaccination course in children primed and boosted with pneumococcal vaccine GSK 1024850A and in age-matched unprimed children	<a href="http://clinicaltrials.gov/show/NCT00950833">http://clinicaltrials.gov/show/NCT00950833</a>	Excluded for all	Follow up 107137	NA
112909	Booster vaccination with pneumococcal vaccine GSK1024850A in primed children and catch-up vaccination in unprimed children	<a href="http://clinicaltrials.gov/show/NCT01030822">http://clinicaltrials.gov/show/NCT01030822</a>	Excluded for all	Follow up 111188	NA
113266	Evaluation of immunological persistence following 3-dose priming with GSK Biologicals' 10-valent pneumococcal conjugate vaccine in study NCT00808444 and safety and immunogenicity following a booster dose of the same vaccine	<a href="http://clinicaltrials.gov/show/NCT01119625">http://clinicaltrials.gov/show/NCT01119625</a>	Excluded for all	Follow up 111654	NA
113978	Immunogenicity and safety study of GlaxoSmithKline Biologicals' GSK2202083A vaccine administered as a booster dose in 12-18 months old healthy children	<a href="http://clinicaltrials.gov/show/NCT01171989">http://clinicaltrials.gov/show/NCT01171989</a>	Excluded for all	Follow up 112157	NA
208136-039	Follow-up to evaluate the the immunogenicity & safety of GSK Biologicals' MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals' Priorix® & Varilrix®.	<a href="http://clinicaltrials.gov/show/NCT00406211">http://clinicaltrials.gov/show/NCT00406211</a>	Excluded for all	Follow up 208136-038	NA
208136-040	Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines	NA	Excluded for all	Follow up 208136-038	NA
208136-041	Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines	NA	Excluded for all	Follow up 208136-038	NA
104420	A phase II study to evaluate the persistence of measles, mumps and rubella antibodies two years after the single dose primary vaccination in study 209762/151.	NA	Excluded for all	Follow up 209762-151	NA
217744-083	Study to assess immunogenicity and reactogenicity of GSK Bio's combined DTPa-HBV-IPV/Hib vaccine in pre-term infants in comparison with term infants, administered as a booster dose to children who previously were primed with 3 doses of GSK Biologicals combined DTPa-HBV-IPV/Hib vaccine	NA	Excluded for all	Follow up 217744-070	NA
101518	A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (Infanrix-hexa) given as a booster at 18-24 months of age to children who have received a three-dose primary immunisation course with the same vaccine in a previous study	NA	Excluded for all	Follow up 217744-090	NA
711202-008	Evaluate the persistence and immune memory induced by a primary vaccination course with GSK Biologicals' MenC-TT (1 formulation) & GSK Biologicals' Hib-MenC-TT (2 formulations) or Meningitec™ in healthy toddlers aged 12-15 mths primed in study 711202/001	<a href="http://clinicaltrials.gov/show/NCT00135564">http://clinicaltrials.gov/show/NCT00135564</a>	Excluded for all	Follow up 711202-001	NA
711866-005	Open, 1-year, phase III, immunogenicity follow-up of subjects who previously received GSK Biologicals' dTpa-IPV vaccine or GSK Biologicals' dTpa (Boostrix™) and Pasteur Mérieux's IPV vaccine (IPV Mérieux()) administered separately, at 4 to 8 years of age in study 711866/001 (dTpa-IPV-001)	NA	Excluded for all	Follow up 711866-001	NA
104756	Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007	<a href="http://clinicaltrials.gov/show/NCT00317109">http://clinicaltrials.gov/show/NCT00317109</a>	Excluded for all	Follow up 759346-007	NA
759348-002	A randomized, controlled, phase II study to evaluate the safety and immunogenicity of 7 different formulations of an investigational vaccination regimen, when administered as a 3-dose primary immunization schedule before 6 months of age, followed by a fourth dose during the second year of life	NA	Excluded for all	Follow up 759348-001	NA
444563-022	A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine	<a href="http://clinicaltrials.gov/show/NCT00263666">http://clinicaltrials.gov/show/NCT00263666</a>	Excluded for all	HIV babies	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
115884	Immunogenicity, safety and reactogenicity study of GSK Biologicals' pneumococcal vaccine (Synflorix™) when administered to children who are at an increased risk of pneumococcal infection	<a href="http://clinicaltrials.gov/show/NCT01746108">http://clinicaltrials.gov/show/NCT01746108</a>	Excluded for all	High-risk babies and no primary (Sp)	NA
759346-009	Study to evaluate immunogenicity, reactogenicity and safety of investigational vaccination regimen as compared to GSK Biological's Hiberix vaccine, extemporaneously mixed with GSK Biological's Tritanrix-HepB, when administered intramuscularly in infants at 6, 10 and 14 weeks of age	NA	Excluded for all	No data	NA
102144	Study to assess immunogenicity and reactogenicity of a booster dose of GSK Biologicals Kft's combined DTPwCSL-HB vaccine as compared to concomitant administration of CSL's DTPw vaccine and GSK Biologicals' hepatitis B vaccine at separate injection sites and to GSK Biologicals' DTPw-HB vaccine	NA	Excluded for all	No data	NA
196131-001	A phase III, partially double blind, randomized, multicentric study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals Kft's combined DTPwCSL-HB vaccine as compared to Commonwealth Serum Laboratory's (CSL's) DTPwCSL (Triple Antigen™) and GSK Biologicals' HBV (Engerix™-B) administered concomitantly at separate injection sites and to GSK Biologicals' DTPw-HB vaccine (Tritanrix™-HepB) when administered to healthy infants at 3, 4 and 5 months of age	NA	Excluded for all	No data	NA
208139-054	Study in infants vaccinated with Engerix-B to evaluate immunogenicity and reactogenicity of following GSK Bio's vaccines: combined DTP-HB vaccine(10g HBsAg)/combined DTP-HB vaccine(5g HBsAg) simultaneous administration of Engerix-B vaccine in right thigh and whole-cell DTP vaccine in left thigh	NA	Excluded for all	No data	NA
209762-146	Open, multicentre study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals live attenuated Measles-Mumps-Rubella vaccine (Priorix) given to healthy children at the age of 12 to 15 months or 4- 6 years	NA	Excluded for all	No data	NA
113171	Safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational vaccination regimen in children aged 12-23 months at the time of first vaccination.	<a href="http://clinicaltrials.gov/show/NCT00985751">http://clinicaltrials.gov/show/NCT00985751</a>	Excluded for all	No data	NA
114174	Impact of GSK Biologicals' 2189242A vaccine on nasopharyngeal carriage, safety and immunogenicity when co-administered with routine EPI vaccines in infants following safety assessment in children aged 2-4 years in The Gambia	<a href="http://clinicaltrials.gov/show/NCT01262872">http://clinicaltrials.gov/show/NCT01262872</a>	Excluded for all	No data	NA
115373	Safety and immunogenicity study of GSK Biologicals' pneumococcal vaccine 2830930A when administered as a single dose in healthy toddlers aged 12-23 months	<a href="http://clinicaltrials.gov/show/NCT01485406">http://clinicaltrials.gov/show/NCT01485406</a>	Excluded for all	No data	NA
217744-086	Single-blind, multicentre, phase IV clinical trial to assess and compare the immunogenicity and reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) and Aventis Pasteur's DTPa-HBV-IPV-Hib vaccine (Hexavac™) given as a primary vaccination course at 2, 4 and 6 months of age.	NA	Excluded for all	No dates file	NA
217744-075	Phase III, open, randomised immunogenicity and reactogenicity study to assess the interchangeability between GSK Bios' DTPa-HBV-IPV/Hib and DTPa-IPV/Hib + HBV at 3rd dose of primary vac. course in children who received HBV vac. at birth and one month of age and DTPa-IPV/Hib vac at 3-4 Mth of age	<a href="http://clinicaltrials.gov/show/NCT00366366">http://clinicaltrials.gov/show/NCT00366366</a>	Excluded for all	No dates file	NA
217744-099	A phase II, randomized, partially blinded clinical trial to evaluate the immunogenicity and reactogenicity of an investigational vaccine regimen of GSK Biologicals as compared to GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) and to the concomitant administration of GSK Biologicals' DTPa-HBV-IPV (Infanrix™ penta) and Hib (Hiberix™) vaccines, when given as a primary vaccination to healthy infants at 2, 3 and 4 months of age	NA	Excluded for all	No dates file	NA
217744-049	Immunogenicity and reactogenicity of GSK Biologicals' DTPa-HBV-IPV and Hib vaccines when administered concomitantly to healthy infants administered as a three-dose primary vaccination course at the age of 1.5, 3.5 and 6 months	<a href="http://clinicaltrials.gov/show/NCT00879827">http://clinicaltrials.gov/show/NCT00879827</a>	Excluded for all	No dates file	NA
347414-016	A phase II, single-blind, randomised, controlled, multicentre study to evaluate the safety, reactogenicity and immunogenicity of two experimental formulations versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix™ or HibTiter™) administered as primary vaccination to infants in their thirth, fourth and fifth months of life, with concomitant administration of SmithKline Beecham Biologicals' DTPa-HBV-IPV vaccine	NA	Excluded for all	No dates file	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
217744-060	Study to assess the immunogenicity and reactogenicity of DTPa-HBV-IPV mixed with Hib vaccine in healthy infants, followed by a dose of the same vaccine administered simultaneously with one dose of oral polio vaccine (OPV)	<a href="http://clinicaltrials.gov/show/NCT01457560">http://clinicaltrials.gov/show/NCT01457560</a>	Excluded for all	No dates file	NA
763674-001	A phase II, open, randomized, controlled study to evaluate an investigational vaccination regimen administered as a three dose primary vaccination course at 2, 3 and 4 months of age.	NA	Excluded for all	No dates file	NA
213501-019	Study to assess immunogenicity and reactogenicity of GSK Bio's quadrivalent diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus influenzae type b conjugate vaccines when mixed extemporaneously and given in a single injection to healthy infants	NA	Excluded for all	No dates file	NA
208108-087	Phase 2 open randomized primary vaccination study to assess the immunogenicity and reactogenicity of GSK Biologicals' Haemophilus influenzae type b conjugate vaccine administered with commercially available DTPw vaccine as compared to GSK Biologicals' Hib administered mixed with GSK Biologicals' DTPw vaccine in healthy infants	NA	Excluded for all	No dates file	NA
101853	A randomized, controlled, phase II study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age.	NA	Excluded for all	No dates file	NA
347414-028	A randomized, controlled, open, phase-II clinical study to evaluate the safety and immunogenicity of an experimental formulation extemporaneously mixed with SmithKline Beecham Biologicals' Haemophilus influenzae type b (Hib) vaccine, administered as a booster dose with DTPa-HBV-IPV to healthy children 12 to 18 months old	NA	Excluded for all	No dates file and no Ab (Nmen)	NA
213503-049	An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of GSK Biologicals' combined Infanrix-IPV+Hib (DTPa-IPV/Hib) vaccine in healthy children aged 17 to 20 months who completed a three-dose primary vaccination course	NA	Excluded for all	No dates file and no primary (av 217744-076, but no PID)	NA
115375	Antibody persistence in children previously vaccinated with three doses of Infanrix hexa™ or Infanrix-IPV/Hib™	<a href="http://clinicaltrials.gov/show/NCT01358825">http://clinicaltrials.gov/show/NCT01358825</a>	Excluded for all	No primary (av 105539, but no PID)	NA
217744-095	Study to assess immunogenicity and reactogenicity of GSK Bio's DTPa-HBV-IPV/Hib vaccine when given as a booster dose to children previously primed at 2-4-6 months of age either with Aventis Pasteurs DTPa-HBV-IPV-Hib vaccine or GSK Bio's DTPa-HBV-IPV/Hib vaccine in study DTPa-HBV-IPV-086	NA	Excluded for all	No primary (av 217744-086 no dates)	NA
763674-002	A phase II open, randomized, controlled study to evaluate an investigational vaccination regimen administered as a three dose primary vaccination course at 2, 3 and 4 months of age.	NA	Excluded for all	No primary (av 763674-001, but no dates)	NA
100448	Long-Term Follow Up Study at Years 16-20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers	<a href="http://clinicaltrials.gov/show/NCT00240500">http://clinicaltrials.gov/show/NCT00240500</a>	Excluded for all	No primary (no av 103860-064)	NA
103860-271	Immunogenicity and protective efficacy of GlaxoSmithKline (GSK) recombinant-DNA hepatitis B vaccine (10 (g) in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical control group.	NA	Excluded for all	No primary (no av 103860-064) and no serology	NA
106390	Study to demonstrate non-inferiority of GSK Biologicals' Hib-MenC given with Infanrix™ penta versus NeisVac-C™ given with Infanrix™ hexa at 3, 5 months of age and persistence prior to a Hib-MenC booster at 11 months and immunogenicity of the booster	<a href="http://clinicaltrials.gov/show/NCT00327184">http://clinicaltrials.gov/show/NCT00327184</a>	Excluded for all	No primary (no av 106388)	NA
109621	Safety, reactogenicity and immunogenicity following booster dose of GSK Biologicals' pneumococcal conjugate vaccine when co-administered with a booster dose of Infanrix-IPV/Hib in preterm born children at 16-18 months of age	<a href="http://clinicaltrials.gov/show/NCT00609492">http://clinicaltrials.gov/show/NCT00609492</a>	Excluded for all	No primary (no av 107737) and no serology	NA
114843	Safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744)	<a href="http://clinicaltrials.gov/show/NCT01453998">http://clinicaltrials.gov/show/NCT01453998</a>	Excluded for all	No primary (no av 113948)	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
100565	An open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' commercially available combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years	NA	Excluded for all	No primary (no av 208127-076)	NA
100386	Evaluate the persistence of immune response of GSK Biologicals' TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose	<a href="http://clinicaltrials.gov/show/NCT00197171">http://clinicaltrials.gov/show/NCT00197171</a>	Excluded for all	No primary (no av 208127-082)	NA
100387	Evaluate the persistence of immune response of GSK Biologicals' TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose	<a href="http://clinicaltrials.gov/show/NCT00197171">http://clinicaltrials.gov/show/NCT00197171</a>	Excluded for all	No primary (no av 208127-082)	NA
100566	Evaluate Persistence of Immune Response of GSK Biologicals' TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose	<a href="http://clinicaltrials.gov/show/NCT00197119">http://clinicaltrials.gov/show/NCT00197119</a>	Excluded for all	No primary (no av 208127-084)	NA
100567	Evaluate Persistence of Immune Response of GSK Biologicals' TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose	<a href="http://clinicaltrials.gov/show/NCT00197119">http://clinicaltrials.gov/show/NCT00197119</a>	Excluded for all	No primary (no av 208127-084)	NA
100568	Evaluate Persistence of Immune Response of GSK Biologicals' TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose	<a href="http://clinicaltrials.gov/show/NCT00197119">http://clinicaltrials.gov/show/NCT00197119</a>	Excluded for all	No primary (no av 208127-084)	NA
100569	Evaluate Persistence of Immune Response of GSK Biologicals' TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose	<a href="http://clinicaltrials.gov/show/NCT00197119">http://clinicaltrials.gov/show/NCT00197119</a>	Excluded for all	No primary (no av 208127-084)	NA
100570	Evaluate Persistence of Immune Response of GSK Biologicals' TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose	<a href="http://clinicaltrials.gov/show/NCT00197119">http://clinicaltrials.gov/show/NCT00197119</a>	Excluded for all	No primary (no av 208127-084)	NA
208355-124	An open, 3.5 year, immunogenicity follow-up of subjects who previously received GSK Biologicals' dTpa vaccine or GSK Biologicals' DTPa vaccine or Chiron Behring's Td vaccine + either Pasteur Merieux's Pa vaccine or GSK Biologicals' pa vaccine, administered as a booster dose at age 4-6 years in study 208355/118 (APV-118)	NA	Excluded for all	No primary (no av 208355-118, but no dates)	NA
208355-123	A phase 3, open, multicenter study of the safety and immunogenicity of a booster dose of SB Bios' Diphtheria and Tetanus toxoids and acellular Pertussis vaccine and Pasteur Mérieux's Haemophilus influenzae type b conjugate vaccine when admin intramuscularly as separate injections(12-18 mths of age)	NA	Excluded for all	No primary (no av 217744-027)	NA
217744-066	Open, randomized, multicentre, phase III clinical trial to assess the reactogenicity and immunogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals' DTPa-HBV-IPV/Hib vaccine, co-administered during the same visit with GSK Biologicals' HAV vaccine (Havrix®), in children in their second ...	NA	Excluded for all	No primary (no av 217744-039, 041, 043 and 057)	NA
217744-061	Phase II, single-blinded, randomized comparative study of the safety and immunogenicity of a booster dose of SB Bios' DTPa-HBV-IPV vaccine compared with Infanrix when both vaccines are co-administered with OmniHIB between 15 and 18 months of age after primary immunization at the age of 2, 4 and 6	NA	Excluded for all	No primary (no av 217744-044)	NA
106744	Multicentre study to assess persistence of antibodies against hepatitis B & immune response to a hepatitis B challenge dose in healthy children 7 to 9 yrs old previously vaccinated with 4 doses of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine	<a href="http://clinicaltrials.gov/show/NCT00356564">http://clinicaltrials.gov/show/NCT00356564</a>	Excluded for all	No primary (no av 217744-048, 039, 058 and 059)	NA
208127-122	An open study to evaluate the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine (schedule 0, 1, 6 months) in healthy children aged 1 to 6 years.	NA	Excluded for all	No primary (no av 3208127-042)	NA
371594-006	A phase II, open, randomized study to assess the immune memory induced by a primary vaccination course of an investigational vaccination regimen and the immunogenicity and reactogenicity of a fourth dose of an investigational vaccination regimen, to healthy toddlers primed in study 371594/004.	NA	Excluded for all	No primary (no av 371594-004)	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
263855-035	Phase IIIb study to evaluate immunogenicity, antibody persistency and reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX vaccines administered to healthy children previously primed with 3 doses of DTPa vaccine compared to placebo (HAVRIX@JUNIOR)	<a href="http://clinicaltrials.gov/show/NCT00544271">http://clinicaltrials.gov/show/NCT00544271</a>	Excluded for all	No primary (Diphtheria, Tetanus, Pertussis), No Ab (HAV)	NA
213503-046	Open, randomised phase IIIb, clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals' DTaP-IPV vaccine, with GSK Biologicals' DTaP and Aventis Pasteur MSD's IPV vaccines administered to healthy children, previously vaccinated with 4 doses of DTaP and polio vaccines, and co-administered with GSK Biologicals' MMR vaccine	NA	Excluded for all	No primary (Measles, Mumps, Rubella, Diphtheria, Tetanus, Pertussis, Polio)	NA
213503-047	Open, randomized, phase II, clinical trial to compare the immunogenicity and safety of a booster dose of GSK Biologicals' DTaP-IPV vaccine (Infanrix®-IPV) co-administered with a booster dose of Merck and Company's M-M-R®II, to that of separate injections of GSK Biologicals' DTaP vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II administered as booster doses to healthy children 4 to 6 years of age.	<a href="http://clinicaltrials.gov/show/NCT00263692">http://clinicaltrials.gov/show/NCT00263692</a>	Excluded for all	No primary (Measles, Mumps, Rubella, Diphtheria, Tetanus, Pertussis, Polio)	NA
213503-048	Safety, immunogenicity&consistency of 3 manufacturing lots of DTaP-IPV vaccine vs separate injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV admd as booster doses to healthy children 4-6 yrs, each co-admd with Merck's MMR vaccine	<a href="http://clinicaltrials.gov/show/NCT00148941">http://clinicaltrials.gov/show/NCT00148941</a>	Excluded for all	No primary (Measles, Mumps, Rubella, Diphtheria, Tetanus, Pertussis, Polio)	NA
111763	Immunogenicity and safety of GSK Biologicals' dTpa-IPV vaccine (Boostrix Polio) as a booster dose in 3 and 4-year-old children	<a href="http://clinicaltrials.gov/show/NCT01245049">http://clinicaltrials.gov/show/NCT01245049</a>	Excluded for all	No primary (Measles, Mumps, Rubella, Diphtheria, Tetanus, Pertussis, Polio)	NA
105909	Comparative study evaluating the immunogenicity & safety of MeMuRu-OKA vaccine & measles-mumps-rubella vaccine (Priorix™) co-administered with varicella vaccine (Varilrix™) in children primed with both measles-mumps-rubella & varicella vaccines	<a href="http://clinicaltrials.gov/show/NCT00352898">http://clinicaltrials.gov/show/NCT00352898</a>	Excluded for all	No primary (Measles, Mumps, Rubella, VZV)	NA
115158	Immunogenicity and safety study of GSK Biologicals' combined measles-mumps-rubella vaccine in subjects four to six years of age (209762)	<a href="http://clinicaltrials.gov/show/NCT01621802">http://clinicaltrials.gov/show/NCT01621802</a>	Excluded for all	No primary (Measles, Mumps, Rubella, VZV, Diphtheria, Tetanus, Pertussis, Polio)	NA
113264	Immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline Biologicals' GSK2036874A vaccine in healthy toddlers	<a href="http://clinicaltrials.gov/show/NCT01106092">http://clinicaltrials.gov/show/NCT01106092</a>	Excluded for all	No primary (routine)	NA
110474	Long-term persistence of hepatitis B antibodies & immune response to a hepatitis B vaccine challenge in 7-8 year old children, previously vaccinated in infancy with GlaxoSmithKline (GSK) Biologicals' HBV vaccine.	<a href="http://clinicaltrials.gov/show/NCT00519649">http://clinicaltrials.gov/show/NCT00519649</a>	Excluded for all	No primary (routine)	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
213503-050	Study to evaluate safety and immunogenicity of a booster dose of DTPa-IPV/Hib at 18 months of age with GSK Biologicals DTPa-IPV/Hib compared to Aventis Pasteurs Pentacel, after an initial primary vaccination series administered at 2, 4, and 6 months of age with Aventis Pasteurs Pentacel	NA	Excluded for all	No primary (routine)	NA
213503-045	Study to compare immunogenicity and reactogenicity of GSK Bio's DTPa-IPV vaccine, with GSK Bio's DTPa (Infanrix) and Aventis MSDs IPV vaccine (Imovax Polio) administered separately to healthy children 4 to 6 years of age	NA	Excluded for all	No primary (routine)	NA
106789	Assess long-term persistence of hepatitis B antibodies & immune response to a hepatitis B vaccine (Engerix-B Kinder) challenge in children aged 4-5 yrs (previously primed & boosted in the 1st 2 yrs of life with DTPa-HBV-IPV/Hib vaccine)	<a href="http://clinicaltrials.gov/show/NCT00411697">http://clinicaltrials.gov/show/NCT00411697</a>	Excluded for all	No primary (routine)	NA
711866-006	A phase III, open study to evaluate the immunogenicity, safety and reactogenicity of GSK Bios' dTpa-IPV vaccine when administered as a booster vaccination to healthy children (6-8 Y) and previously vaccinated with 4 doses of DTPw and at least 3 doses of OPV/ IPV vaccines	NA	Excluded for all	No primary (routine)	NA
711866-001	A study to assess the lot-to-lot consistency of GSK Biologicals dTpa-IPV vaccine administered to healthy children 4 to 8 years of age, previously vaccinated with four doses of DTPa or DTPa-based combination vaccines and at least 3 doses of OPV or IPV	NA	Excluded for all	No primary (routine)	NA
201532	Evaluation of immunogenicity, safety and reactogenicity of GSK Biologicals' dTpa booster vaccine (263855) (Boostrix) administered as a booster dose in healthy Russian subjects	<a href="http://clinicaltrials.gov/show/NCT03311659">http://clinicaltrials.gov/show/NCT03311659</a>	Excluded for all	No primary (routine)	NA
104005	Phase IIIb, open, randomized, multicenter study to assess the immunogenicity & safety of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in Indian infants when given at 6-10-14 weeks of age or at 2-4-6 months of age	<a href="http://clinicaltrials.gov/show/NCT00316147">http://clinicaltrials.gov/show/NCT00316147</a>	Excluded for all	No sero file	NA
105987	A single-blind, randomized, controlled, multinational study for the evaluation of safety of GlaxoSmithKline (GSK) Biologicals' investigational vaccination regimen compared to monovalent Haemophilus influenzae type b (Hib) control vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.	<a href="http://clinicaltrials.gov/show/NCT00345579">http://clinicaltrials.gov/show/NCT00345579</a>	Excluded for all	No sero file	NA
103812	Assess reactogenicity & safety of a booster of either Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ given (single-blind) at 15-18 (Philippines)/15-24 mths (Thailand) & a dose of Mencevax™ ACWY at 24-30 mths (open label)	<a href="http://clinicaltrials.gov/show/NCT00228917">http://clinicaltrials.gov/show/NCT00228917</a>	Excluded for all	No sero file	NA
104171	Assess reactogenicity & safety of a booster of either Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ given (single-blind) at 15-18 (Philippines)/15-24 mths (Thailand) & a dose of Mencevax™ ACWY at 24-30 mths (open label)	<a href="http://clinicaltrials.gov/show/NCT00228917">http://clinicaltrials.gov/show/NCT00228917</a>	Excluded for all	No sero file	NA
100791	Study to assess immunogenicity and non-inferiority of investigational vaccination regimen as compared to Tritanrix-HepB/Hiberix and as compared to Meningitec when administered to healthy infants	<a href="http://clinicaltrials.gov/show/NCT00317187">http://clinicaltrials.gov/show/NCT00317187</a>	Excluded for all	No sero file	NA
200147	Safety and immunogenicity study of 2 formulations of GSK Biologicals' varicella vaccines given as a 2-dose course in the second year of life.	<a href="http://clinicaltrials.gov/show/NCT02570126">http://clinicaltrials.gov/show/NCT02570126</a>	Excluded for all	No sero file No primary (Measles, Mumps, Rubella)	NA
205249	A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Meningococcal B Recombinant Vaccine When Administered concomitantly with Routine Vaccines to Healthy Infants in Taiwan.	<a href="http://clinicaltrials.gov/show/NCT02173704">http://clinicaltrials.gov/show/NCT02173704</a>	Excluded for all	Novartis study	NA
205240	A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal group B Vaccine When Administered Concomitantly with GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants	<a href="http://clinicaltrials.gov/show/NCT02106390">http://clinicaltrials.gov/show/NCT02106390</a>	Excluded for all	Novartis study	NA
205450	A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants	<a href="http://clinicaltrials.gov/show/NCT00657709">http://clinicaltrials.gov/show/NCT00657709</a>	Excluded for all	Novartis study. No sero file.	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
205453	A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13	<a href="http://clinicaltrials.gov/show/NCT01139021">http://clinicaltrials.gov/show/NCT01139021</a>	Excluded for all	Novartis study. No sero file.	NA
205399	A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.	<a href="http://clinicaltrials.gov/show/NCT00721396">http://clinicaltrials.gov/show/NCT00721396</a>	Excluded for all	Novartis study. No sero file.	NA
106481	Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants	<a href="http://clinicaltrials.gov/show/NCT00420745">http://clinicaltrials.gov/show/NCT00420745</a>	Excluded for all	Pre-term babies	NA
217744-090	A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib vaccine (Infanrix hexa()) given as a primary vaccination course at 2, 4 and 6 months of age to pre-term infants.	NA	Excluded for all	Pre-term babies	NA
103860-280	Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs	<a href="http://clinicaltrials.gov/show/NCT00343915">http://clinicaltrials.gov/show/NCT00343915</a>	Excluded for all	Teenagers	NA
101695	Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs	<a href="http://clinicaltrials.gov/show/NCT00343915">http://clinicaltrials.gov/show/NCT00343915</a>	Excluded for all	Teenagers and no primary (av 103860-280)	NA
101696	Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs	<a href="http://clinicaltrials.gov/show/NCT00343915">http://clinicaltrials.gov/show/NCT00343915</a>	Excluded for all	Teenagers and no primary (av 103860-280)	NA
101697	Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs	<a href="http://clinicaltrials.gov/show/NCT00343915">http://clinicaltrials.gov/show/NCT00343915</a>	Excluded for all	Teenagers and no primary (av 103860-280)	NA
101698	Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs	<a href="http://clinicaltrials.gov/show/NCT00343915">http://clinicaltrials.gov/show/NCT00343915</a>	Excluded for all	Teenagers and no primary (av 103860-280)	NA
107625	Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants	<a href="http://clinicaltrials.gov/show/NCT00480324">http://clinicaltrials.gov/show/NCT00480324</a>	Excluded for all	No Ab (Diphtheria, Tetanus, Pertussis, HBV)	NA
111188	Primary vaccination course in healthy children receiving the pneumococcal vaccine GSK 1024850A co-administered with Tritanrix™-HepB/Hib at 6, 10 and 14 weeks of age	<a href="http://clinicaltrials.gov/show/NCT00814710">http://clinicaltrials.gov/show/NCT00814710</a>	Excluded for all	No primary (HBV), No Ab baseline (Diphtheria, Tetanus, Pertussis, HiB)	NA
113615	Feasibility study of GlaxoSmithKline Biologicals' GSK2202083A vaccine in healthy infants at 2, 4 and 12 months of age	<a href="http://clinicaltrials.gov/show/NCT01090453">http://clinicaltrials.gov/show/NCT01090453</a>	Excluded for all	No Ab (Rotavirus), No Ab baseline (Diphtheria, Tetanus, Pertussis, HBV, HiB, Nmen, Polio, Sp)	NA
107005	To assess safety, reactogenicity and immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine, when co-administered with DTPa-combined vaccines and MenC or Hib-MenC vaccines during the first 6 months of age.	<a href="http://clinicaltrials.gov/show/NCT00334334">http://clinicaltrials.gov/show/NCT00334334</a>	Excluded for all	No primary (HBV), No Ab baseline (Diphtheria, Tetanus, Pertussis,	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
				HiB, Nmen, Polio, Sp)	
105539	An open, randomized, phase IIIa study to evaluate the safety and immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine, when administered intramuscularly according to a 2-4-11 months vaccination schedule	<a href="http://clinicaltrials.gov/show/NCT00307034">http://clinicaltrials.gov/show/NCT00307034</a>	Excluded for all	No Ab baseline (Diphtheria, Tetanus, Pertussis, HBV, HiB, Polio)	NA
759348-003	A randomized, controlled, phase II study to evaluate the safety and immunogenicity of four different formulations of GlaxoSmithKline (GSK) Biologicals' investigational vaccination regimen, when administered as a 3-dose primary immunization schedule beginning before 6 months of age.	NA	Excluded for all	No Ab baseline (Diphtheria, Tetanus, Pertussis, HBV, HiB, Polio)	NA
111654	Non-inferiority of a commercial lot of the pneumococcal vaccine GSK1024850A compared to a clinical lot.	<a href="http://clinicaltrials.gov/show/NCT00808444">http://clinicaltrials.gov/show/NCT00808444</a>	Excluded for all	No Ab baseline (Diphtheria, Tetanus, Pertussis, HiB, Polio, Rotavirus, Sp), No primary (HBV)	NA
347414-008	Study to assess immunogenicity and safety of GSK Biologicals' investigational vaccination regimen administered concomitantly in separate injections with GSK Biologicals' DTPa-IPV/Hib vaccine as a primary vaccination course to healthy infants at 2-4-6 months of age and as a booster dose at 12 to 18 months of age	NA	Excluded for all	No Ab (Diphtheria, Tetanus, Pertussis, HBV, Polio)	NA
106445	Study to demonstrate non-inferiority of GSK Biologicals' Hib-MenC with Priorix™, versus MenC-CRM197 vaccine with Hiberix™ & Priorix™ in toddlers primed with Hib but not MenC & to evaluate persistence up to 5 years after vaccination.	<a href="http://clinicaltrials.gov/show/NCT00326118">http://clinicaltrials.gov/show/NCT00326118</a>	Excluded for all	No Ab (Measles, Mumps, Rubella), No primary (HiB, Diphtheria, Tetanus, Pertussis)	NA
107058	Evaluate immunogenicity, safety & reactogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine given as catch-up immunization in children older than 7 mo of age or as 3-dose primary immunization in children before 6 mo of age	<a href="http://clinicaltrials.gov/show/NCT00345358">http://clinicaltrials.gov/show/NCT00345358</a>	Excluded for all	No Ab baseline (Diphtheria, Tetanus, Pertussis, HiB, Polio)	NA
347414-020	A Phase III, randomized, single blind study to assess the immune response induced by Prevenar™ (Wyeth Lederle) when administered to healthy infants with DTPa-HBV-IPV/Hib, compared to an investigational vaccination regimen as a 3-dose primary vaccination course at a monthly interval starting at 8-16 Weeks of age	NA	Excluded for all	No primary (HBV)	NA
112640	Immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' pneumococcal vaccine GSK1024850A following primary and booster vaccination of healthy Japanese children	<a href="http://clinicaltrials.gov/show/NCT01027845">http://clinicaltrials.gov/show/NCT01027845</a>	Excluded for all	No primary (HBV), No vaccine concentration (HiB, Pertussis)	NA
217744-069	Immunogenicity and safety of GSK Biological's DTPa-HBV-IPV/Hib vaccine or DTPa-IPV/Hib co-administered with HBV vaccine as primary and booster vaccination in healthy infants born to hepatitis B surface antigen negative mothers	<a href="http://clinicaltrials.gov/show/NCT00880477">http://clinicaltrials.gov/show/NCT00880477</a>	Excluded for all	No Ab baseline (HBV, Polio)	NA
217744-077	A phase III, double-blind, randomized, multicenter primary vaccination study to bridge the DTPa-HBV-IPV vaccine manufactured according to the large scale manufacturing process with the DTPa-HBV-IPV vaccine manufactured by the small scale manufacturing process when administered intramuscularly to infants at 2, 4 and 6 months of age, co-administered with Merck's Hib conjugate vaccine (Liquid PedvaxHIB®) in a separate injection at 2 and 4 months of age	NA	Excluded for all	No Ab (HiB)	NA
208136-022	Study to evaluate immunogenicity and safety of one dose of GSK Bios' combined measles-mumps-rubella-varicella vaccine compared to concomitant administrations of GSK Bios' measles-mumps-rubella vaccine and varicella vaccine	NA	Excluded for all	No primary routine (Measles)	NA

Study ID	Study title	Link	Exclusion	Reason	Inclusion per pathogen
217744-076	An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals' combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle's meningococcal group C conjugate vaccine.	NA	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
711202-001	Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals' MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals' Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life	<a href="http://clinicaltrials.gov/show/NCT00135486">http://clinicaltrials.gov/show/NCT00135486</a>	Included	Included	Diphtheria, HBV, HiB, IPV (1, 2, 3), Nmen (C), Pertussis-a (FHA, PRN, PT), Tetanus
110058	Immunogenicity of GlaxoSmithKline Biologicals' MMRV vaccine (208136) vs. ProQuad®, when coadministered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age.	<a href="http://clinicaltrials.gov/show/NCT00578175">http://clinicaltrials.gov/show/NCT00578175</a>	Excluded for all	No Ab method (VZV, Mumps), No primary (Sp)	NA
111870	A phase II, randomized, observer blind, controlled, multicenter study to assess immunogenicity and antibody persistence following vaccination with GSK's candidate combined measles, mumps, and rubella vaccine (MMR) versus M-M-R® II as a first dose, both administered subcutaneously at 12-15 months of age, concomitantly with hepatitis A vaccine (HAV), varicella vaccine (VV) and pneumococcal conjugate vaccine (PCV) but at separate sites.	<a href="http://clinicaltrials.gov/show/NCT00861744">http://clinicaltrials.gov/show/NCT00861744</a>	Excluded for all	No Ab method (VZV, Mumps), No primary (Sp)	NA
103860-277	Phase III study of immunogenicity and safety of 3 doses of GSK Biologicals' thimerosal-free hepatitis B vaccine compared to the US-licensed GSK Biologicals' preservative-free hepatitis B vaccine when administered intramuscularly on a 0, 1, 6-month schedule to healthy infants in their first two weeks of life	NA	Excluded for all	Outside age range (HBV)	NA
402764-004	A phase III, open, randomized study to evaluate the immunogenicity and reactogenicity of investigational vaccination regimens	NA	Excluded for all	Outside age range (Diphtheria, Tetanus, Pertussis, Nmen, HBV, HiB)	NA
213501-018	Study to evaluate immunogenicity, safety and reactogenicity of two different immunization regimens against hepatitis B, diphtheria, tetanus, pertussis and Haemophilus influenzae type b (Hib)diseases in healthy infants primed with a birth dose of GSK Biologicals hepatitis B	NA	Excluded for all	Outside age range (Diphtheria, Tetanus, Pertussis, HBV, HiB)	NA
104977	Non-inferiority of one formulation of GSK Biologicals' DTPw-HBV/Hib to 2 formulations of GSK Biologicals' DTPw-HBV/Hib with respect to the immune response to the PRP antigen, when administered to healthy infants at 6, 10, 14 weeks of age	<a href="http://clinicaltrials.gov/show/NCT00473668">http://clinicaltrials.gov/show/NCT00473668</a>	Excluded for all	Latitude range <80% (Diphtheria, Tetanus, Pertussis, HBV, HiB)	NA
104567	Phase IIIb, multicentre study to assess safety & immunogenicity of GSK Biologicals' combined DTPa/Hib (Infanrix/Hib) vaccine vs separate administration of DTPa (Infanrix) & Hib (Hiberix) vaccines in healthy infants 3,4,&5 months of age as compared with the separate administration of DTPa and Hib vaccines at different injection sites.	<a href="http://clinicaltrials.gov/show/NCT00412854">http://clinicaltrials.gov/show/NCT00412854</a>	Excluded for all	Latitude range <80% (Diphtheria, Tetanus, Pertussis, HiB)	NA
792014-001	A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity (including immune memory), reactogenicity and safety of three different formulations of the GSK Biologicals' combined Haemophilus influenzae type b-meningococcal serogroups CY conjugate vaccine given concomitantly with Infanrix® penta and Prevenar®, versus ActHIB® and Meningitec® given concomitantly with Infanrix® penta and versus ActHIB® given concomitantly with Infanrix® penta and Prevenar® in infants according to a 2-4-6 month schedule.	<a href="http://clinicaltrials.gov/show/NCT00127855">http://clinicaltrials.gov/show/NCT00127855</a>	Excluded for all	Latitude range <80% (Diphtheria, Tetanus, Pertussis, Nmen, HBV, HiB, Polio, Sp)	NA
103792	A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals' oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose	<a href="http://clinicaltrials.gov/show/NCT00289172">http://clinicaltrials.gov/show/NCT00289172</a>	Excluded for all	Latitude range <80% (Rotavirus)	NA
115992	Two-dose primary vaccination with either GSK Biologicals' 10-valent pneumococcal vaccine (Synflorix™) or Pfizer's Prevenar 13™ or both vaccines followed by a booster dose of Synflorix™	<a href="http://clinicaltrials.gov/show/NCT01641133">http://clinicaltrials.gov/show/NCT01641133</a>	Excluded for all	Latitude range <80% (Sp)	NA

RCT = Randomized controlled trial, Ab = Antibody immunogenicity, HAV = Hepatitis A virus, HBV = Hepatitis B virus, HiB = *Haemophilus influenzae Type B*, VZV = Varicella Zoster virus, Sp = *Streptococcus pneumoniae*, Nmen = *Neisseria meningitidis*, FHA = filamentous hemagglutinin, PRN = pertactin; PT = pertussis toxoid, NA = not applicable.

**Stable 2. Summary of analytical methods, target antigens, and serological thresholds for immunogenicity assessment.** Overview of the laboratory assays and predefined cut-off values used to evaluate the immune response for each pathogen included in the studies.

Pathogen	Method	Antigen	Cut-off	Unit
Diphtheria	ELISA	Anti-diphtheria	0.10	IU/mL
	PRNT	Anti-diphtheria	0.016	IU/mL
HAV	ELISA	Anti-hav	15.00	mIU/mL
HBV	ELISA	Anti-hbv	10.00	mIU/mL
<i>H. influenzae type B</i>	ELISA	Anti-hib	0.15	µg/mL
Polio (Inactive)	PRNT	Anti-polio 1	8.00	ED50
	PRNT	Anti-polio 2	8.00	ED50
	PRNT	Anti-polio 3	8.00	ED50
Measles	ELISA	Anti-measles	150.00	mIU/mL
<i>N. meningitidis</i>	ELISA	Anti-men A	0.30	µg/mL
	ELISA	Anti-men C	0.30	µg/mL
	BAC	Anti-men A	8.00	Dilution
	BAC	Anti-men C	8.00	Dilution
Mumps	ELISA	Anti-mumps	231.00	U/mL
	PRNT	Anti-mumps	24.00	ED50
Pertussis (acellular)	ELISA	Anti-pertussis PT	15.00	EU/mL
	ELISA	Anti-pertussis FHA	5.00	EU/mL
	ELISA	Anti-pertussis PRN	5.00	EU/mL
Pertussis (whole)	ELISA	Anti-pertussis PT	15.00	EU/mL
Rotavirus	ELISA	Anti-rotavirus IgA	20.00	U/mL
Rubella	ELISA	Anti-rubella	4.00	IU/mL
<i>S. pneumoniae</i>	ELISA	Anti-strep 01	0.05	µg/mL
	ELISA	Anti-strep 03	0.05	µg/mL
	ELISA	Anti-strep 04	0.05	µg/mL
	ELISA	Anti-strep 05	0.05	µg/mL
	ELISA	Anti-strep 06a	0.05	µg/mL
	ELISA	Anti-strep 06b	0.05	µg/mL
	ELISA	Anti-strep 07f	0.05	µg/mL
	ELISA	Anti-strep 09v	0.05	µg/mL
	ELISA	Anti-strep 14	0.05	µg/mL
	ELISA	Anti-strep 18c	0.05	µg/mL
	ELISA	Anti-strep 19a	0.05	µg/mL
	ELISA	Anti-strep 19f	0.05	µg/mL
	ELISA	Anti-strep 23f	0.05	µg/mL
	OPA	Anti-strep 01	8.00	Dilution
	OPA	Anti-strep 03	8.00	Dilution
	OPA	Anti-strep 04	8.00	Dilution
	OPA	Anti-strep 05	8.00	Dilution
	OPA	Anti-strep 06a	8.00	Dilution
	OPA	Anti-strep 06b	8.00	Dilution
	OPA	Anti-strep 07f	8.00	Dilution
	OPA	Anti-strep 09v	8.00	Dilution
	OPA	Anti-strep 14	8.00	Dilution
	OPA	Anti-strep 18c	8.00	Dilution
OPA	Anti-strep 19a	8.00	Dilution	
OPA	Anti-strep 19f	8.00	Dilution	
OPA	Anti-strep 23f	8.00	Dilution	
Tetanus	ELISA	Anti-tetanus	0.10	IU/mL
VZV	IFA	Anti-vzv	4.00	mIU/mL

HAV = Hepatitis A virus, HBV = Hepatitis B virus, VZV = Varicella Zoster virus, FHA = filamentous hemagglutinin, PRN = pertactin, PT = pertussis toxoid, ELISA = Enzyme-linked immunosorbent assay, OPA = Opsonophagocytosis assay, PRNT = Plaque reduction neutralization test, IFA = Immunofluorescence assay, BAC = Serum bactericidal assay.

**Stable 3. Randomized clinical trials and the number of participants included in each pathogen-antigen subset.**

Pathogen	Antigen	Method	Doses	Studies	Participants
<b>Main analyses</b>					
Diphtheria	Anti-diphtheria	ELISA	3	28	6267
HAV	Anti-hav	ELISA	1	1	1022
HBV	Anti-hbv	ELISA	3	8	2043
<i>H. influenzae type B</i>	Anti-hib	ELISA	3	27	5516
Polio (Inactive)	Anti-polio 1	PRNT	3	15	3343
Measles	Anti-measles	ELISA	1	24	20845
<i>N. meningitidis</i>	Anti-men C	ELISA	3	15	4903
Mumps	Anti-mumps	ELISA	1	21	11694
Pertussis (whole-cell)	Anti-pertussis PT	ELISA	3	13	4102
Rotavirus	Anti-rotavirus IgA	ELISA	2-3	29	7191
Rubella	Anti-rubella	ELISA	1	24	20847
<i>S. pneumoniae</i>	Anti-strep 04	ELISA	3	19	7358
Tetanus	Anti-tetanus	ELISA	3	29	2133
VZV	Anti-vzv	IFA	1	18	8786
<b>Additional antigens</b>					
<i>N. meningitidis</i>	Anti-men A	ELISA	3	5	2056
Polio (Inactive)	Anti-polio 2	PRNT	3	15	3270
Polio (Inactive)	Anti-polio 3	PRNT	3	15	3179
Pertussis (acellular)	Anti-pertussis PT	ELISA	3	28	9302
Pertussis (acellular)	Anti-pertussis FHA	ELISA	3	28	9305
Pertussis (acellular)	Anti-pertussis PRN	ELISA	3	28	9335
<i>S. pneumoniae</i>	Anti-strep 01	ELISA	3	16	6667
<i>S. pneumoniae</i>	Anti-strep 03	ELISA	3	6	2800
<i>S. pneumoniae</i>	Anti-strep 05	ELISA	3	16	6670
<i>S. pneumoniae</i>	Anti-strep 06a	ELISA	3	12	3826
<i>S. pneumoniae</i>	Anti-strep 06b	ELISA	3	19	7316
<i>S. pneumoniae</i>	Anti-strep 07f	ELISA	3	16	6702
<i>S. pneumoniae</i>	Anti-strep 09v	ELISA	3	19	7344
<i>S. pneumoniae</i>	Anti-strep 14	ELISA	3	19	7335
<i>S. pneumoniae</i>	Anti-strep 18c	ELISA	3	19	7345
<i>S. pneumoniae</i>	Anti-strep 19a	ELISA	3	12	3910
<i>S. pneumoniae</i>	Anti-strep 19f	ELISA	3	19	7333
<i>S. pneumoniae</i>	Anti-strep 23f	ELISA	3	19	7349
<b>Additional immunogenicity measurements</b>					
Diphtheria	Anti-diphtheria	PRNT	3	4	197
Mumps	Anti-mumps	PRNT	1	7	5051
<i>N. meningitidis</i>	Anti-men A	BAC	3	5	1784
<i>N. meningitidis</i>	Anti-men C	BAC	3	15	4889
<i>S. pneumoniae</i>	Anti-strep 01	OPA	3	15	4016
<i>S. pneumoniae</i>	Anti-strep 03	OPA	3	5	2266
<i>S. pneumoniae</i>	Anti-strep 05	OPA	3	15	3967
<i>S. pneumoniae</i>	Anti-strep 04	OPA	3	15	3999
<i>S. pneumoniae</i>	Anti-strep 06a	OPA	3	11	1978
<i>S. pneumoniae</i>	Anti-strep 06b	OPA	3	15	3183
<i>S. pneumoniae</i>	Anti-strep 07f	OPA	3	15	3853
<i>S. pneumoniae</i>	Anti-strep 09v	OPA	3	15	3921
<i>S. pneumoniae</i>	Anti-strep 14	OPA	3	15	3996
<i>S. pneumoniae</i>	Anti-strep 18c	OPA	3	15	3919
<i>S. pneumoniae</i>	Anti-strep 19a	OPA	3	10	1791
<i>S. pneumoniae</i>	Anti-strep 19f	OPA	3	15	3878
<i>S. pneumoniae</i>	Anti-strep 23f	OPA	3	15	3919
<b>Multivariate analyses</b>					
MMRV	Anti-measles	ELISA	1	14	6944
	Anti-mumps	ELISA			
	Anti-rubella	ELISA			
	Anti-vzv	IFA			
MMR	Anti-measles	ELISA	1	21	11592
	Anti-mumps	ELISA			
	Anti-rubella	ELISA			
Hib-Men	Anti-hib	ELISA	3	14	2087
	Anti-men C	ELISA			

DTP (acellular)	Anti-diphtheria	ELISA	3	20	1684
	Anti-tetanus	ELISA			
	Anti-pertussis PT	ELISA			
DTP (whole-cell)	Anti-diphtheria	ELISA	3	6	221
	Anti-tetanus	ELISA			
	Anti-pertussis PT	ELISA			
<i>N. meningitidis</i>	Anti-men A	ELISA	3	5	2051
	Anti-men C	ELISA			
	Anti-strep 04	ELISA			
<i>S. pneumoniae 7-serotypes</i>	Anti-strep 06b	ELISA	3	9	951
	Anti-strep 09v	ELISA			
	Anti-strep 14	ELISA			
	Anti-strep 18c	ELISA			
	Anti-strep 19f	ELISA			
	Anti-strep 23f	ELISA			
	Anti-strep 01	ELISA			
<i>S. pneumoniae 10-serotypes</i>	Anti-strep 04	ELISA	3	10	2773
	Anti-strep 05	ELISA			
	Anti-strep 06b	ELISA			
	Anti-strep 07f	ELISA			
	Anti-strep 09v	ELISA			
	Anti-strep 14	ELISA			
	Anti-strep 18c	ELISA			
	Anti-strep 19f	ELISA			
	Anti-strep 23f	ELISA			
	Pertussis (acellular)	Anti-pertussis PT			
Anti-pertussis FHA		ELISA			
Anti-pertussis PRN		ELISA			
Polio (Inactive)	Anti-polio 1	PRNT	3	15	3061
	Anti-polio 2	PRNT			
	Anti-polio 3	PRNT			

HAV = Hepatitis A virus, HBV = Hepatitis B virus, VZV = Varicella Zoster virus, FHA = filamentous hemagglutinin, PRN = pertactin, PT = pertussis toxoid, ELISA = Enzyme-linked immunosorbent assay, OPA = Opsonophagocytosis assay, PRNT = Plaque reduction neutralization test, IFA = Immunofluorescence assay, BAC = Serum bactericidal assay.

## References

1. Voysey, M. *et al.* Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells. *Vaccine* **34**, 1657–1664 (2016).
2. Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. *Nat. Rev. Immunol.* **16**, 626–638 (2016).
3. Voysey, M. *et al.* The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses : An Individual Participant Meta-analysis. *JAMA Pediatr.* **171**, 637–646 (2017).
4. Siegrist, C.-A. & Aspinall, R. B-cell responses to vaccination at the extremes of age. *Nat. Rev. Immunol.* **9**, 185–194 (2009).
5. Jilg, W., Schmidt, M. & Deinhardt, F. Vaccination against hepatitis B: comparison of three different vaccination schedules. *J. Infect. Dis.* **160**, 766–769 (1989).
6. Zaman, K. *et al.* Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial. *Vaccine* **39**, 5814–5821 (2021).
7. Siegrist, C.-A. The challenges of vaccine responses in early life: selected examples. *J. Comp. Pathol.* **137 Suppl 1**, S4–9 (2007).
8. Lucinde, R. K. *et al.* Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review. *Vaccine* **39**, 5095–5105 (2021).